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ABBREVIATIONS 
 
Cer      Ceramide 
ER      Endoplasmic reticulum 
FAs      Fatty acids 
FFAs      Fatty free acids 
GBM       Glioblastoma multiforme 
GlcCer      Glucosylceramide 
GSL      Glycosphingolipids 
LacCer      Lactosylceramide 
PH      Pleckstrin Homology  
SM       Sphingomyelin 
Sph       Sphingosine 
S1P        Sphingosine-1-phosphate 
T2D      Type 2 diabetes 
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ABSTRACT 
 
Cancer and diabetes are among the most common diseases in western societies. 
Sphingolipids, a class of lipids ubiquitously present in eukaryotic membranes, play a key 
role in the regulation of different signal transduction pathways involved in the modulation of 
many cellular functions [1, 2]. The past two decades have seen increased interest in the 
bioactive sphingolipids ceramide (Cer) and sphingosine-1-phosphate (S1P). Cer, a central 
molecule of sphingolipid metabolism, is involved in the control of many cell-stress 
responses, including  growth arrest, senescence and cell death [3]. On the other hand, several 
studies have proposed a crucial role of S1P in cell growth and survival, cell migration, 
angiogenesis, and inflammation [3]. Thus, Cer and S1P can differentially regulate cell death 
and survival by controlling opposing signaling pathways [4]. So far, a large amount of 
studies has clarified the complexity of the interplay between S1P, Cer and sphingolipid 
metabolism and these implications in the etiology of several human diseases. Effectively, 
deregulation of sphingolipid metabolism is implicated in numerous diseases, and 
accumulating evidence has shown a clear indication that sphingolipids have important role 
in the pathogenesis of diabetes and cancer [5].  
Very recently, it is emerging a pivotal role of Cer traffic from the Endoplasmic Reticulum 
(ER) to the Golgi apparatus in the regulation of sphingolipid metabolism. In fact, Cer 
transport is a highly regulated step in the sphingolipid biosynthesis. Two main mechanisms 
are involved in Cer transport from ER to the Golgi apparatus: a protein-mediated transport, 
operated by CERT [6, 7] and a CERT-independent vesicular transport. Moreover, several 
studies reported that ER is a critical intracellular organelle involved in the control of cell fate 
[8, 9]. In this light, Cer accumulation in the ER appears to be a key element in the promotion 
of cell death in different human diseases, as well as in glioblastoma and diabetes.  
In light of these findings, in my Ph.D. course I wanted to evaluate in cellular models of  
glioblastoma (GBM) and type 2 diabetes (T2D) the role of Cer transport in the regulation of 
cell fate. 
 
Part 1: Glucolipotoxicity impairs ceramide flow from the ER to the Golgi apparatus in INS-1 
-cells 
T2D is the most common form of diabetes characterized by insulin resistance and β-cell 
dysfunction. The etiology of T2D is not well established but it is know that loss of insulin 
secretion is directly linked to a loss of function and death of pancreatic β-cells [10]. 
Glucolipotoxicity is a condition  determined by  the combined action of elevated glucose and 
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free fatty acids (FFAs) levels that exerts deleterious effects on pancreatic -cell function and 
survival. Several mechanisms have been proposed for glucolipotoxicity-induced β-cell 
dysfunction, and, among them, ER stress and elevations of the proapoptotic sphingolipid Cer 
appear to play key roles. Moreover, Cer accumulation due to glucolipotoxicity can be 
associated to the induction of ER stress. As in other cells, in the INS-1 insulinoma cell line, 
two main mechanisms are involved in Cer transport from the ER to the Golgi apparatus: a  
CERT-mediated transport [6, 11], and a CERT-independent vesicular transport. 
Glucolipotoxic conditions, obtained with 0.4 mM palmitate and 30 mM glucose 
administration, strongly affected both of them by reducing CERT protein synthesis and 
activity, and the rate of Cer vesicular traffic, thus promoting Cer accumulation in the ER. 
[11, 12]. The two Cer transport mechanisms are effectively involved in the control of 
sphingolipid metabolism, participating in the regulation of Cer accumulation in the ER 
involved in pancreatic -cell function and death during T2D. 
 
Part 2: The stimulation of Cer traffic from the ER to the Golgi apparatus S1P-
dependent as a survival factor in T98G glioma cells. 
GBM is the most common malignant primary brain tumor in adults and one of the most 
lethal human cancers [13]. S1P and Cer have emerged as bio-effectors molecules, involved 
in both glioblastoma development and resistance [3, 14-17]. Several lines of evidence 
indicated that, different anticancer drugs, including etoposide, exert cytotoxic effects also 
promoting accumulation of Cer in the ER. Thus, the transport of Cer from ER to Golgi 
apparatus could be represent a key pathway for limiting Cer accumulation in the ER and 
escape from cell death. Moreover, we recently demonstrated that vesicular-mediated Cer 
transport is positively regulated by the pro-survival pathway phosphatidylinositol 3-
phosphate kinase (PI3K)/Akt [18], known effectors of extracellular S1P.  
In T98G glioma cells, S1P treatment was able to increase vesicular Cer transport from the 
ER to the Golgi apparatus by PI3K/Akt pathway activation, inducing Cer conversion to SM 
and glycosphingolipids (GSL). In these cells, the cytotoxic Cer accumulation in the ER 
promoted by the anticancer drug etoposide was strongly reduced after S1P administration. 
S1P, by enhancing Cer traffic, act as pro-oncogenic factor, favoring both the reduction of the 
pro-apoptotic Cer at the ER and the synthesis of complex sphingolipids. By this mechanism 
S1P also stimulates the generation of new membranes, functional to cell growth and 
consequently to the tumor survival and progression. 
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STATE OF THE ART 
 
Shpingolipids 
Sphingolipids represent a heterogeneous class of lipids that contains backbone of sphingoid 
bases and are essential constituents of eukaryotic cell membranes. For long time they have 
been considered merely as structural components, fundamental in the definition of the 
membrane bilayers. In the last 20 years, advances in biochemical and molecular research led 
to the identification of sphingolipids acting as intra- and extra-cellular messengers involved 
in the regulation of crucial aspects of cell biology such as cell growth, death, migration, 
senescence and inflammatory response [3].  
Sphingolipids are amphipathic molecules, characterized by a hydrophilic (or polar head) and 
a hydrophobic (or tail) portion. Cer (Fig.1) represents the structural element common to all 
sphingolipids. It consists of a long-chain sphingoid base, linked via amide bond to a long-
chain fatty acid, mainly palmitic (C16) or stearic acid (C18) Sphingosine (Sph), an amino-
alcohol containing 18-20 carbon atoms (C-18 or C-20) and characterized by the presence of 
a double bond across C4-C5, is the most frequent sphingoid base constituting Cer in 
humans, followed, in very small proportions, by C-18/C-20 sphinganine (which lacks the 
double bond C4-C5). Both are in the trans D-erythro form. 
Cer is the central building block of all sphingolipids, and represents the hydrophobic 
portion, or tail, of these molecules. Through its primary alcoholic residue, Cer can be 
conjugated to different hydrophilic groups, which represent the polar head of sphingolipids. 
Cer binding to phosphocholine or saccharidic structures leads to the generation of 
sphingomyelins (SM) and glycosphingolipids (GSL), respectively. In GSL, the 
oligosaccharide chain, linked to Cer through a -glycosidic bond, may contain 15-20 
saccharide units, among which, the most frequent are glucose, galactose, N-
acetylglucosamine, N-acetylgalactosamine and different species of sialic acid. Furthermore, 
both the sphingoid base (sphingosine) and Cer may exist in the phosphorylated form in 
correspondence with the carbon in position 1 (C-1) [19, 20]. Sphingolipids are ubiquitous 
membrane components, being present in different organelle membranes and particularly 
abundant in the plasma membrane. Cer is present in small amounts within cell membranes, 
as it functions primarily as an intermediate of complex sphingolipid metabolism and acts as 
a cell signalling mediator [21]. 
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In biological plasma membranes, SM and GSL represent the major sphingolipids, displaying 
an asymmetric or polarized distribution, and play important roles in the regulation of 
membrane fluidity and sub-domain structures. 
 
 
Figure 1:   Ceramide chemical structure  
 
In particular, bth SM and GSLs are mainly localized in the outer leaflet of the cell 
membrane. GLS show a distribution on the membrane specific for each cell type, which can 
vary with differentiation and neoplastic transformation [20]. 
Sphingolipids, thanks to their amphipathic properties, are able to diffuse laterally within the 
membrane and, together with cholesterol and specific proteins, may give rise to 
microdomains, specialized platforms able to compartmentalize cellular processes by serving 
as organizing centres for the assembly of signalling molecules [22].  
 
Sphingolipid metabolism 
The metabolic pathway of sphingolipids consists of a complex network of synthetic and 
degradative reactions. Sphingolipids can originate from both the "de novo synthesis" or from 
the degradation of complex sphingolipids (Fig. 2) [15]. 
The “de novo” biosynthesis of sphingolipids starts at the cytosolic leaflet of the ER and 
begins with the condensation of palmitoyl-CoA with L-serine. This reaction is catalyzed by 
the enzyme serine-palmitoyl transferase (SPT) and leads to the formation of 3-
ketosphinganine, which is subsequently reduced to sphinganine by a NADPH-dependent 
oxidoreductase, the 3- ketosphinganine reductase. Sphinganine is the substrate of the 
(dihydro)-Cer synthase (CerS), which uses an acyl donor to bind sphinganine to a fatty acid, 
forming dihydroCer. In mammalian cells, six different isoforms of CerS have been recently 
identified and are encoded by six different genes, members of the LASS family (Longevity 
Ceramide (N-acyl-D-erytro-sphingosine 
D-erytro-sphingosine 
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Assurance Genes). Each of these genes specifically synthesise one of the several Cer species 
that differ in the fatty acid chain length. In particular, LASS1 is involved in the production 
of C18Cer, LASS2 of C22Cer, LASS3 of C18/C24Cer, LASS4 of C20Cer, LASS5 and LASS6 
of C16Cer and C14/C16Cer respectively [23, 24]. The product of the reaction catalyzed by 
CerS, dihydroCer, is desaturated in position 4,5 of the sphingoid base by a NADPH-
dependent oxydoreductase, the dihydroCer desaturase (DES), with the consequent formation 
of Cer [25]. All the enzymes involved in the de novo biosynthesis of Cer are localized in the 
ER membrane, acting on the cytosolic surface of the same, and the reaction products remain 
there anchored. 
Cer is the common precursor for the synthesis of all complex sphingolipids. Through its 
hydroxyl group at the carbon in position 1, Cer can bind to additional functional groups, 
generating GSL, Cer 1-phosphate and SM.  
GLS derive from the conjugation of the Cer primary alcoholic residue with one or more 
saccharide units, through β-glycosidic bond.  
Galactosylceramide (GalCer) is synthesized from Cer and UDP-galactose by the 
galactosyltransferase, enzyme expressed at the luminal side of the ER membrane in 
Schwann cells and oligodendrocytes. GalCer, together with its sulphate derivative, sulfatide 
synthesized at the Golgi,  is an important lipidic component of myelin (formed by Schwann 
cells in the peripheral nervous system and oligodendrocytes in the central nervous system), 
and confers rigidity and stability to the membranes, allowing a correct conduction of nerve 
impulses [26]. 
Glucosylceramide (GlcCer) is obtained from Cer and UDP-glucose, through a reaction 
catalyzed by GlcCer synthase (GCS), which is localized at the cytosolic leaflet of the Golgi 
apparatus [27]. Therefore, GlcCer biosynthesis requires an efficient transport mechanism of 
Cer from the cytoplasmic side of the ER to the cytoplasmic side of the cis-Golgi. Once 
synthesized, GlcCer can be routed directly to the plasma membrane (via a vesicular system), 
or it can be further modified by subsequent glycosylations, with the consequent production 
of more complex glycosphingolipids, such as gangliosides. This process is catalyzed by 
different glycosyl-transferases acting by associating to GlcCer individual saccharide units, 
following a precise sequential order [14]. The enzymes involved in these reactions are 
located and act in the luminal surface of the Golgi cisternae; thus a flippase mechanisme 
mediating the translocation of GlcCer from the cytoplasmic to the luminal side of the cis-
Golgi has be active [28, 29]. GlcCer can be transported from the cis-Golgi cisterna to the 
trans Golgi network (TGN) through a non-vesicular mechanism that requires the FAPP2 
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protein. FAPP2 contains a PH domain, similar to FAPP1 at the N-terminus, that  recognizes 
both  PI4P and Arf1 localized at the TGN [7].  
Cer can also undergo phosphorylation of the hydroxyl group of the carbon in position 1 by 
the Cer kinase (CERK), with the consequent formation of Cer 1-phosphate (C1P) [3]. The 
subcellular localization of this enzyme has not been definitely identified, but it seems to be 
at the level of the plasma membrane, the Golgi apparatus, and the cytoplasm [30].  
SM represents approximately 10% of the lipids present in mammalian cells. SM synthesis is 
based on the transfer of phosphocholine from phosphatidylcholine to Cer, with the 
production of a diacylglycerol (DAG) molecule. This reaction is catalyzed by SM synthase 
(SMS). Several studies suggest the existence of two different enzymatic SMS isoforms: 
SMS1, localized in the luminal side of the cis/medial Golgi apparatus and SMS2, primarily 
localized to the plasma membrane [3, 31]. Experimental evidence has shown that about 90% 
of the de novo synthesis of SM occurs in the cis/medial Golgi, and only a small percentage 
occurs at the level of the plasma membrane. Therefore, most of SM biosynthesis, as well as 
that of GlcCer, requires a mechanism of Cer transport from the ER, where it is synthesized, 
to the Golgi apparatus. The localization of SMS2 at the plasma membrane suggests its role 
as a regulator of SM and Cer levels for signalling pathways and signal transduction [14]. 
Sphingolipids reach their final destination at the plasma membrane, mainly following the 
vesicular flow of exocytosis from the ER or the Golgi apparatus to the plasma membrane. 
Membrane GSL are constitutively degraded by a process involving endocytosis and the 
endo-lysosomal district; the enzymatic steps of this degradation process include 
exoglycohydrolases requiring an acidic pH, guaranteed within the lysosomal or endosomal 
vesicles, in order to perform their catalytic activity. These enzymes catalyze the degradation 
of GSL, determining the sequential hydrolytic detachment of monosaccharides [32] from 
Cer. 
SM degradation is catalyzed by sphingomyelinase (SMase), an enzyme able to hydrolyze the 
SM phosphodiester bond, with the consequent formation of Cer and phosphocholine. Three 
isoforms of this enzyme have been described and distinguished, according to their 
subcellular localization and the optimum pH, in acidic, neutral, and alkaline SMase. The 
acid SMase is located mainly in the lysosomal compartment. Another isoform of acidic 
SMase has been identified, due to a splice variant in the transcription of the encoding gene; 
this enzyme can be secreted or localized in the outer membrane leaflet [3, 33]. The neutral 
SMase has different subcellular locations including the inner leaflet of the plasma 
membrane, ER, Golgi, and even the nucleus [33].  
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Figure 2: Subcellular compartmentalization of sphingolipid metabolism 
Image from M.Maceyka
 
and S. Spiegel
, 
Nature 510; 58–67 2014 
 
The localization of alkaline SMase is more restricted, being mainly expressed in the 
intestinal tract, and in the bile where it participates to SM digestion [34].  
Cer is degraded by ceramidases (CDases); three isoforms of CDases have been identified 
and classified by their pH optima as acidic, neutral and alkaline CDases. These CDases are 
located at the plasma membrane, lysosome, and ER/Golgi complex, respectively [35]. These 
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enzymes hydrolytically cleave Cer in fatty acid and sphingosine (Sph) [14]. Notably, Sph 
origin is exclusively catabolic, since it only derives from sphingolipids degradation [36]. 
Cer-derived Sph can be recycled or undergo phosphorylation in position C1 with the 
generation of S1P (Fig.3) by sphingosine kinases (as described below). S1P can be 
metabolized through the irreversible cleavage in position C2-C3, to hexadecenal and 
phosphoethanolamine in a reaction catalyzed by the S1P lyase enzyme, located on the ER 
cytosolic side [37]. This reaction, and the SPT catalyzed one, are the reactions of the entire 
sphingolipid metabolism which occur in only one direction, the enzymes catalysing the 
opposite reaction being absent. S1P can also be dephosphorylated back to Sph through a 
reaction catalyzed by either lipid phosphate, or S1P specific phosphatases [38-40]. 
 
 
Figure 3: Sphingosine-1-phosphate (S1P) chemical structure 
 
Concerning to recycling pathway, the products obtained from sphingolipids degradation 
such as saccharide residues, fatty acids and, particularly, Sph can be reused for the synthesis 
of complex sphingolipids. In this process, Sph produced from SM and GSL catabolism 
reaches the ER where it is N-acylated to Cer. Cer can then be used for the biosynthesis of 
complex sphingolipids, as described in de novo biosynthesis (Fig.2). This pathway is called 
"salvage pathway" [3].  
The Sph recycling process is an energy advantage to cells and, in different cell types, such as 
cells of glial origin, may constitute the principal pathway of sphingolipids synthesis [41]. 
 
ER to Golgi Ceramide transport pathways 
To date, two transport mechanisms are known to operate in the cell to transfer Cer from ER 
to the Golgi apparatus for the synthesis of complex sphingolipids: a CERT-dependent, and a 
vesicular CERT-independent pathway. 
 
CERT-dependent  Ceramide transport 
CERT  was originally isolated as a protein  that restores SM synthesis in a SM-defcient CHO 
mutant cell line, LY-A [6]. CERT is a 68-kDa cytosolic protein that is identical to 
GPBPΔ26, a splice variant of Goodpasture antigen-binding protein (GPBP) that lacks 26 
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amino acids in the serine rich region. CERT and GPBP (also termed CERTL) both have a 
Cer transfer activity between membranes in a non-vesicular manner (Fig.4). CERT 
transports Cer in an ATP-dependent and non-vesicular manner, specifically for the SM 
biosynthesis CERT contains different domains and motifs: the C-terminal steroidogenic 
acute regulatory protein (StAR)-related lipid transfer (START) domain (∼230 amino acids); 
two phenylalanines (FF) in an acidic tract (FFAT) motif at the N-terminal side of the 
START domain; a serine repeat (SR) motif and the N-terminal PH domain (∼100 amino 
acids). The structure of the START domain reveals a long amphiphilic cavity in which one 
Cer molecule is located. At the far end of the cavity, the amide and hydroxyl groups of Cer 
form hydrogen bonds with specific amino acid residues that are involved in stereospecific 
Cer recognition. Moreover, the wall of the hydrophobic cavity limits the size and shape for 
ceramides [42] working as a molecular measuring device similar to the bacterial membrane 
acyltransferase, PagP [43]. The START domain extracts Cer from donor membranes 
favoring ceramides with a chain length of 14–20 carbon atoms than ceramides with longer 
acyl chains (i.e. C22–C24) [[44].  
The N-terminus of CERT contains a pleckstrin homology (PH) domain that predominantly 
recognizes phosphatidylinositol 4-phosphate (PI4P) produced by phosphatidylinositol 4-
kinase III beta (PtdIns-4K IIIβ) that co-localize with PtdIns-4KIIIβ in cis/medial-Golgi 
compartments. The PH domain of CERT is required for its efficient association with the 
Golgi via PI4P[6]. Moreover, a coiled-coil motif is found in the middle region of CERT, 
between the PH and START domains, containing the consensus sequence EFFDAXE, 
namely the FFAT motifs [45]. The FFAT motifs interact with the ER-resident type II 
membrane proteins, VAP-A and VAP-B (vesicle-associated membrane protein- associated 
proteins). VAPs recruit CERT to the cytosolic surface of ER membranes, and it is this 
interaction which is crucial for the association with the ER membrane [44]. Cer binding to 
CERT may result in conformational changes leading to alternating exposure and 
concealment of PH and FFAT domains, resulting in unidirectional Cer transport between the 
ER and Golgi apparatus [46]. CERT can exists in hyperphosphorylated and 
hypophosphorylated forms. Mass spectrometry analysis confirms that 7–9 serines/threonines 
can be  phosphorylated in the SR region. Two kinases are involved in the phosphorylation of 
the SR motif: the first kinase is protein kinase D (PKD), which phosphorylates  serine 132, 
and the second kinase is an isoform of casein kinase 1 (CK1γ2) [7]. In normally growing 
cells, CERT exists mainly as the hyperphosphorylated forms. CERT phosphorylations 
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inhibit both START domain-mediated Cer transfer activity and PH domain-mediated PI4P-
binding activity thus PKD and CKIγ2 function as negative regulators of CERT. 
The hyperphosphorylated CERT is dephosphorylated by protein phosphatase 2Cε (PP2Cε), a 
transmembrane protein of the ER. PP2Cε interacts with VAP-A and its activity on CERT is 
dependent on the expression of VAP-A. Saito S. at al. demonstrated that the 
dephosphorylation enhances both the localization of CERT to the Golgi and the interaction 
of CERT with VAP-A, indicating that PP2Cε activates Cer CERT-dependent transport 
from the ER to the Golgi [7]. 
 
 
Figure 4: CERTL and CERT structures  
   Modified image from:  R.J. Perry, N. D. Ridgway Biochimica et Biophysica Acta 1734   
  (2005) 220 – 234. 
 
Vesicular CERT- independent Ceramide transport 
Cer can be also transported to the Golgi apparatus from ER-derived vesicles. Vesicular 
transport represents a crucial mechanism by which Cer travels as membrane component of 
small carrier vesicles that origin from a donor compartment and fuse with specific target 
membranes. The vesicular transport of Cer is thought to operate by molecular machineries 
similar to those of proteins [22], although the molecular mechanism for the recruitment of 
Cer into COPII-coated vesicles is unknown. Cer vesicular transport appears crucial for 
production of SM and/or GlcCer. In fact, biosynthesis of SM is, at least in part, dependent 
on the vesicular transport and CERT downregulation inhibits SM biosynthesis, but not that 
of GlcCer in different cells [47].  
Intriguingly, PI3K/Akt has been shown to regulate the ER-Golgi vesicular transport of Cer 
and consequently Cer levels in C6 glioma cells [18], implying this traffic in Cer-mediated 
signaling too.   
 
Ceramide and Sphingosine 1-phosphate as bioactive messengers 
Cer is a central hub in sphingolipid metabolism. It acts as an intracellular second messenger 
by regulating different intracellular effectors involved in many different processes such as 
cell growth, differentiation, senescence, necrosis, proliferation and apoptosis. Increased of 
12 
 
Cer levels can lead to cell growth arrest or cell death. Cer is able to activate the 
serine/threonine protein phosphatases PP1 and PP2A. These phosphatases act on several 
substrates such as retinoblastoma protein (pRB), Bcl-2, c-JUN, PKCα, SR proteins and Akt 
which are all implicated in cell pathways regulating proliferation and apoptosis. Cer-
mediated activation of PP1 seems to be involved in the cell cycle arrest in the G1 phase, due 
to the dephosphorylation of pRB [16, 48]. Furthermore, PP1 induces the dephosphorylation 
of SR proteins, a family of serine/arginine-domain proteins known modulators of mRNA 
splicing, thus inducing the alternative splicing of the genes encoding Bcl-X and caspase-9, 
generating pro-apoptotic splice variants [49, 50]. Mitochondrial membrane potential can also 
be altered by Cer, probably through the PP2A-mediated dephosphorylation of Bcl-2, causing 
its inactivation and thus favouring the apoptotic process [51]. Cer also activates Cathepsin D 
protease which in turn recruits and activates, via proteolytic breakdown, the pro-apoptotic 
protein BID resulting in the induction of apoptosis [16].  
Another important Cer target is PKC-ζ. Increased levels of Cer induce the activation of this 
protein, by phosphorylation. The activated PKC-ζ, in turn phosphorylates the hnRNP A1 
factor, involved in the mechanisms of alternative splicing. This factor might be involved in 
the alternative splicing of genes involved in apoptosis [52]. 
Cer can also exert an antiproliferative role through the inhibition of MAPK pathway, 
promoting the dephosphorylation of ERK1/2 (extracellular signal regulated protein kinase 1 
and 2), serine/threonine kinases belonging to the family of MAP kinase (MAPK) [53]. These 
proteins, if dephosphorylated, are inactive and thus not able to migrate into the nucleus to 
promote the expression of genes involved in cell proliferation [54, 55]. ERK1/2 inhibition 
induced by Cer can be associated with the ability of this mediator to activate, in systems 
"cell free", the serine/threonine protein phosphatase PP2A [56-58]. 
Many stimuli activating acid SMase at the plasma membrane induce the formation of Cer-
enriched domain that trap and cluster signalling proteins [59]. In these domains, the initial 
signal can be amplified via concentration and oligomerization of proteins that transmit 
signals across the plasma membrane. Such clustering has been shown for proteins associated 
with apoptotic signalling. Fas receptors, Fas-associated death domain-containing protein 
(FADD) and caspase-8 have been shown to cluster within Cer-enriched domain [60]. 
Furthermore, Cer can induce apoptosis by forming membrane channels in mitocondria, 
which are large enough to cytochrome c release [61].  
Cer levels can be regulated by different mechanisms, such as modulation of Cer metabolic 
enzymes and/or Cer transport mechanisms, thus producing other sphingolipids that may 
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have different cellular effects. Reduction of intracellular Cer levels is therefore one 
mechanism that can mediate cell survival.  
S1P, the other relevant sphingolipid messenger, plays a role in proliferation, cell growth, cell 
survival, cell migration, inflammation, angiogenesis, vasculogenesis and resistance to 
apoptotic cell death. S1P is formed from sphingosine and ATP in a reaction catayzed by the 
enzyme sphingosine kinase (SphK). So far, two isoenzymes, known as SphK1 and SphK2, 
have been identified in mammals. SphK1 and SphK2 display different subcellular 
localization, tissue distribution and temporal expression pattern during development [62] 
SphK1 is largely cytoplasmic and can acutely associate with the plasma membranes, 
phagosomes, and endosomal vesicles, whereas SphK2 even if present in the cytoplasm is 
predominately in the nucleus [63]. 
S1P can interact, in an autocrine and/or paracrine manner, with five specific transmembrane 
receptors (S1P1-5) coupled to different G-proteins and displaying tissue-specific expression 
patterns [64]. Through its receptor S1P can activate several signal transduction pathways, 
and thus elicit a variety of cell-specific responses controlling cell behaviour [65]. The 
activation of these G proteins coupled receptors results in the modulation of different 
signalling pathway such as ERK, c-Jun N-terminal kinase (JNK), the small GTPases of the 
Rho family (Rho and Rac), phospholipase C (PLC), adenylate cyclase and PI3K/Akt 
signalling [65-67]. Through its receptors, S1P is able to regulate different cellular processes, 
such as cell proliferation, motility, invasion, cytoskeletal rearrangement, angiogenesis, 
vascular maturation and lymphocyte trafficking and actions.  
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Part 1: Glucolipotoxicity impairs Ceramide flow 
from the ER to the Golgi apparatus in INS-1 cells 
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INTRODUCTION 
Diabetes is a complex disease characterized by a chronic abnormal elevation of plasma 
glucose concentrations. It is one of the major causes of death worldwide and the World 
Health Organization (WHO) proposes this disease to become the seventh leading cause of 
death by 2030.  
Diabetes may be classified into two groups based on its pathophysiology. Type 1 diabetes is 
caused by a lack of insulin due to the destruction of insulin-producing beta cells in the 
pancreas by the immune system. Often, type 1 diabetes is diagnosed when most of -cells 
have already been damaged, so afflicted people need daily insulin treatment to survive. Type 
1 diabetes typically occurs in children and young adults, though it can appear at any age 
[10]. 
 
Type 2 diabetes 
T2D, the most common form of diabetes, is a multi-factorial disease characterized by insulin 
resistance and β-cell dysfunction. In this pathological state, peripheral target tissues (skeletal 
muscle, liver, and adipose) are unable to respond effectively to normal circulating 
concentrations of insulin. Thus, insulin resistance is generally reversed by enhanced 
secretion of insulin from the β-cells, and T2D only develops in those individuals when β- 
cells do not produce enough insulin.[68] The etiology of T2D is not well established but it is 
know that loss of insulin secretion is directly linked to a loss of function and death of 
pancreatic β-cells [10]. The development of this pathology results from genetic 
susceptibility, social and environmental factors. T2D develops most often in middle-aged 
and older people. Moreover, accumulating evidence suggests that T2D is often associated 
with alteration in lipid metabolism, high levels of circulating lipids and is strongly 
associated with obesity. Free fatty acids (FFAs) are important physiological nutrients for β- 
cell, and they are readily degraded by β-oxidation acting as supplemental fuel able to 
potentiate insulin secretion in response to glucose However, chronically elevated levels of 
circulating FFAs have been proposed to induce peripheral insulin resistance and impairment 
of β-cell insulin secretion, a phenomenon that has been called “lipotoxicity” [69]. Pietiläinen 
and colleagues, in a study on weight-discordant twins, demonstrated that obese individuals 
showed signs of insulin resistance in adipose tissue, if compared with their lean twins [70] . 
This alteration was due to significant differences in adipose tissue fatty acid composition; in 
particular, a reduction of stearic, linoleic, and α-linolenic acids, and increased amount of 
palmitoleic and arachidonic acids in obese twins.[69] However, the molecular mechanisms 
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underlying the pathogenesis of lipotoxicity in pancreatic β-cells has not been elucidated. A 
growing amount of studies demonstrates that the excessive adipose tissue increase has 
further consequences at the cellular and subcellular levels of β-cells; in particular, at the ER 
that is commonly affected in obese subjects. Chronic exposure of β-cells to high FFAs and 
glucose levels, also termed glucolipotoxicity, results in β-cell dysfunction and loss by ER 
stress and oxidative stress  resulting in apoptosis [71] (Fig.1). 
 
 
 
Figure 1: Mechanisms of β-cells failure in Type 2 diabetes   
                Modified image from Rev. Bras. Hematol. Hemoter. vol.32  2010   
 
ER stress in Type 2 diabetes 
ER is a organelle responsible for the synthesis, post-translational modification and folding of 
peptides, synthesis of lipids, and control of the intracellular calcium homeostasis. 
Accumulating evidence suggests that ER stress is correlated to T2D. During diabetes, the 
high insulin demand induces a markedly increase of pro-insulin synthesis and folding in the 
ER of β-cells to counteract hyperglycemia. Under this condition, ER function progressively 
worsened and this led to an adaptive defense known as the “unfolded protein response” 
(UPR), a mechanism to restore the ER homeostasis. Moreover, elevated levels of ER stress 
markers were observed in pancreatic islet of diabetic human subjects [5].  When severe or 
prolonged ER stress occurs, the URP switches in to β-cells death. FFA overload beyond the 
esterification capacity of β-cells in the ER is associated with ER stress response, thus 
triggering β-cell death or dysfunction [5]. Impaired ER-to-Golgi trafficking itself can 
contribute directly to the reduction of insulin production by compromising the maturation of 
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pro-insulin in post-Golgi compartments. ER stress has been recognized to induce 
inflammation and there are direct links between ER stress/UPR and both local and systemic 
inflammation. ER stress is associated with the production of pro-inflammatory cytokines, 
mainly IL-1β. IRE1α is a key factor involved in the transcription of inflammatory genes, and 
its interaction with TNF receptor–associated factor 2 (TRAF2) promotes NF-κB and JNK 
pathways. Moreover, IRE1α/TRAF2 can also activate AP1 transcription factor, which 
promotes the expression of inflammatory cytokines [72]. JNK may also be involved in the 
FFAs-induced pancreatic β-cell dysfunction. The key role of the NF-kB pathway in the 
induction of inflammatory responses in T2D, has been highlighted in several studies [5]. 
Fatty acids (FAs), in particular saturated FAs induce the expression of NF-κB through Toll-
like receptor 4 (TLR4) signaling. An improvement in insulin sensitivity was observed in 
animal model of FFA-induced insulin resistance when the gene encoding for TLR4 was 
mutated [5].  Recent studies, discovered a role of Src in JNK activation and the upregulation 
of two proteins, DP5 and PUMA, involved in palmitate-induced β-cell apoptosis [73]. A role 
for caspase-2 induction in ER stress-induced cell death has also been reported. ER stress 
may also lead to β-cell dysfunction by degradation of insulin mRNA through IRE1a 
activation [5]. ER stress and induction of UPR can also result in mithocondrial dysfunction 
and ROS generation. Moreover, when conditions of glucotoxicity and lipotoxicity are 
combined (glucolipotoxic conditions), β-cell stress responses can be amplified, potentiating 
effects of elevated glucose and FFAs [5] (Fig.2). 
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Figure 2: The model of ER stress-associated inflammation and cell death  
                Modified image from: Front. Genet., 25 July 2014 [74] 
 
Ceramide in Type 2 diabetes 
Recent advances in the study of sphingolipid metabolism, have underlined the relevant roles 
that sphingolipids play in pancreatic β-cells. Sphingolipid metabolites such as Cer, GSL, 
S1P and gangliosides modulate many β-cell signaling pathways and processes involved in β-
cell diabetic disease such as apoptosis, β-cell cytokine secretion, ER-to-Golgi vesicular 
trafficking, islet autoimmunity and insulin gene expression [75].  
In particular, Cer, has been implicated as an important effector in the FAs-induced apoptosis 
of pancreatic β-cells [76]. Fatty acids, particularly saturated FAs have been shown to 
promote ER stress to induce β-cell apoptosis [77]. The toxic effect of saturated FAs may be 
related to the formation of Cer. Infact, different observations from several studies 
demonstrate that Cer is involved in ER stress-induced β-cell apoptosis. Both Cer synthesis 
via the de novo pathway and via SM hydrolysis have been reported to cause ER stress-
induced β-cell apoptosis [5]. A study of Lei et al demonstrated that induction of β-cell 
apoptosis in response to strong ER stress is associated to Cer accumulation due to the 
activation of neutral SMase. Inhibition of neutral SMase protected β-cell from ER stress 
Inflammation 
Cell death 
Restoring ER homeostasis 
Cell survival 
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induced apoptosis, demonstrating the role of Cer in ER stress-induced cell death. Cer 
increase in ER stress also activates intrinsic mitochondrial pathway of apoptosis in β-cells 
by altering the mitochondrial membrane permeability and release of cytochrome c [78]. ER 
stress and induction of UPR can also result in ROS generation, and the role of ROS, both as 
upstream and downstream, to Cer activation is well known [5].  
 
Ceramide and mechanisms of β-cell apoptosis 
Several studies indicate that extensive apoptosis of pancreatic β-cell is a relevant event in 
the pathogenesis of diabetes. The involvement of Cer in this process is also well established 
[5]. A large number of evidence suggests that Cer-induced pancreatic β-cell apoptosis is 
mediated by extrinsic death receptors, ER stress, mitochondrial dysfunction with cytocrome 
c release and  ROS production [5]. 
Cytokines and saturated FAs promote the activation of extrinsic pathway leading apoptosis 
of pancreatic β-cell. Binding of different cytokines such as tumor necrosis factor-alpha 
(TNF- α), Interleukin-1 beta (IL-1β) and Interferon-gamma (IFN-γ) to their specific 
receptors results in the activation of the estrinsic pathway that activate typically caspase-8, 
which in turn activates downstream effector caspases (i.e. caspase-3) [79] (Fig.3).  
Pancreatic β-cells when exposed to cytokines show an increase in Fas expression; moreover, 
pancreatic β-cells that lacks caspase-8 has shown protection against both Fas and Cer-
induced cell death [80]. Liadis et al. demonstrated that caspase-3 knockout mice were 
protected from diabetes [81], underlying the role of caspase cascade in β-cell apoptosis. 
A group of proteins belonging to the B-cell lymphoma-2 (Bcl-2) family regulates the 
intrinsic mitochondrial pathway. The apoptotic action of Cer is mediated by the recruitment 
and activation of pro-apoptotic Bax at the mitochondria. Different studies, have 
demonstrated that  induction of Cer formation from SM, determines the translocation and 
activation of Bax at the mitochondria with cytochrome c release [5]. In agreement with this, 
depletion of Bax or overexpression of Bcl-2, prevented Cer-induced apoptosis [5].  
The intrinsic mitochondrial pathway is also involved in the FAs-induced β-cell apoptosis 
(Fig. 3). It has been reported that treatment of β-cells to saturated FAs results in enhanced 
mitochondrial membrane permeability and cytochrome c release [82]. Furthermore, 
reduction in Bcl-2 expression and Bax up-regulation was also observed when β-cells were 
exposed to FAs [5]. Cer also inhibits Akt activation, and thereby, promotes the 
mitochondrial membrane permeability, and cytochrome c release by preventing the Akt 
induced inactivation of pro-apoptotic Bcl-2 members [83]. 
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Figure 3: Schematic representation of mechanism of beta-cell apoptosis caused by     
           ceramide 
          Image from Galadari S. et al.  Lipids in Health and Disease 2013 12:98 [5]  
 
Role of ceramide in insulin resistance  
Increasing evidence demonstrates that Cer plays significant role in insulin resistance. 
Studies using cultures of skeletal muscles and adipocytes treated with Cer provided the first 
evidence of Cer implication in insulin resistance. These experiments have demonstrated that 
long treatment with palmitate of cultured myotubes, L6 skeletal muscle cells, 3 T3 
adipocytes  and cardiac myocytes [5] increases Cer accumulation and promotes Akt 
inhibition. Further studies using different approaches to block the enzymes of Cer 
biosynthesis, have demonstrated the role of Cer in saturated FA-induced insulin resistance 
[84] [85]. In agreement with this, reduction of Cer level, prevented the palmitate-induced 
Cer accumulation and improved insulin signalling [86].  
Animal models studies using mice fed with high-fat diet show an  increased expression of 
Cer synthase [87] Furthermore, in animal models, infusion of lipid emulsion increases 
muscle Cer content and decrease peripheral insulin sensitivity. These effects were blocked 
by inhibitors of de novo Cer biosynthesis enzyme SPT, indicating the role of Cer [88]. 
Recently, a study that compared the effect of saturated FAs and unsaturated FAs on insulin 
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sensitivity in rats, has demonstrated that both of these treatments decrease glucose uptake 
and Akt activation, but ceramide increase occurs only with saturated FAs oil infusion 
Analysis of several studies using lipid with different composition in unsaturated and 
saturated FAs, indicates that Cer plays a role only in insulin resistance induced by saturated 
fats. In another study, lipid infusion in humans is found to increase skeletal muscle Cer and 
decrease insulin sensitivity [89].  
 
Ceramide and insulin synthesis 
Several studies reveal that Cer is involved also in the reduction of insulin synthesis by 
decreasing insulin mRNA levels in pancreatic β cells. Saturated FAs also have been shown 
to increase Cer and impair insulin gene expression. This effect was reversed by inhibitors of 
de novo Cer synthesis [5].  Furthermore, treatments that increase endogenous Cer are able to 
reduce insulin mRNA levels [90, 91]. Two mechanisms of inhibition of insulin gene 
transcription by Cer have been proposed. First, Cer activates JNK which inhibits insulin 
gene transcription both via c-jun-dependent, and oxidative stress-dependent pathways [5]. 
Second, Cer directly activates PKCζ which phosphorylates and inactivates Pancreatic and 
duodenal homeobox gene-1 (PDX-1), a transcription factor which regulates insulin gene 
expression [5]. Moreover, Cer has also been shown to decrease transcription of the Glut-4 
gene (Fig.4). In conclusion, these results suggest that Cer modulates signaling pathways 
involved in the transcriptional regulation of the insulin gene. 
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Fig. 4: Major pathways in insulin receptor signaling and mechanism of ceramide in insulin 
resistance. Activation of insulin receptor leads to Akt activation. Once activated, Akt reduce blood 
glucose level by inducing glucose uptake, glycogen synthesis, protein synthesis and fatty acid 
synthesis. Akt also act by inhibiting gluconeogenesis. Some of the metabolic effects of insulin may 
also be mediated via other signaling branches than those depicted. Ceramide causes insulin 
resistance by PP2A and PKCζ mediated inhibition of Akt and MLK-3 mediated inhibition of IRS. 
Ceramide may also decrease Glut-4 gene transcription. Cer, Ceramide.   
Image from Galadari S. et al. Lipids in Health and Disease 2013 12:98[5]    
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AIM 
 
Glucolipotoxicity is the condition in which the combined action of elevated glucose and 
FFAs levels synergizes in exerting deleterious effects on pancreatic -cell function and 
survival [69, 92, 93]. Several evidence suggests that this condition is a key component in 
T2D, contributing to β-cell dysfunction and death (reviewed in [94]). Among different 
FFAs, palmitate represents one of the major species particularly potent in reducing β-cell 
viability of β-cells from primary rodent, as well as in human islets [77, 95, 96]. Several 
mechanisms have been proposed for glucolipotoxicity-induced β-cell dysfunction and 
failure, and, among them, ER stress and elevations of the proapoptotic sphingolipid Cer 
appear to play key roles. Moreover, these two processes appear to be strictly connected [97-
99] and Cer accumulation due to glucolipotoxicity can be associated to the induction of ER 
stress.  
Cer synthesized in the ER is transferred to the Golgi apparatus, where it is subsequently 
converted to SM, GlcCer and more complex GSL [100]. As mentioned above, two pathways 
are known to transport Cer from the ER to the Golgi apparatus: a protein-mediated transport, 
by the soluble Cer transfer protein CERT (for SM formation) [6, 11, 22, 42], and a CERT-
independent vesicular traffic (for the biosynthesis of SM or GlcCer) [11, 12, 22]. The two 
ways of Cer transport coexist separately contributing to the regulation of Cer metabolism 
and levels in cells. Increased levels of Cer in ER may be due to enhanced Cer biosynthesis 
and/or decreased Cer utilization. Several data suggest that the accumulation of Cer in the ER 
compartment of -cells is crucial in determining -cell fate. The aim of this study was to 
gain insights into the molecular mechanisms of glucolipotoxicity to better understand the 
relationship between Cer accumulation and ER stress, particularly focusing on Cer 
metabolism and transport mechanisms from the ER to the Golgi, involved in 
glucolipotoxicity of INS-1 cells. 
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MATERIALS AND METHODS 
 
Materials  
All reagents were of analytical grade unless otherwise stated. The culture medium RPMI 
1640 was purchased from Lonza (Basel, Switzerland). L-glutamine, sodium pyruvate 
solution, penicillin/streptomycin, dimethyl sulfoxide (DMSO), palmitate, glucose, Hepes, 
bovine serum albumin fraction V (BSA), fatty acid free-BSA, 3-[4,5-dimethylthiazol-2-
yl]2,5-diphenyl tetrazolium bromide (MTT), leupeptin, aprotinin, wortmannin (Wm), 
Thapsigargin (Tg), Kodak Biomax film, HPLC grade water, tetrahydrofuran (THF), 
methanol, LC-MS grade water, formic acid and ammonium formate were purchased from 
Sigma-Aldrich (St. Louis, MO, USA). Fetal calf serum (FCS) was from Euroclone (Pero, 
Milano, Italy). LY294002 was from Cayman Chemical (Ann Arbor, MI, USA). 
Lipofectamine 2000 and the Stealth RNAi were from Invitrogen (Carlsbad, CA, USA). D-
erythro-[3-
3
H]sphingosine (Sph) (19.7 Ci/mmol),  was from PerkinElmer Life Science 
(Boston, MA, USA). Pepstatin was from Roche Applied Sciences (Mannheim, Germany). 
High performance thin layer chromatography (HPTLC) silica gel plates were from Merck 
(Darmstadt, Germany). The Golgi marker Texas red wheat germ agglutinin (WGA), 6-((N-
(7-nitrobenz-2-oxa-1,3-diazol-4-yl) amino) hexanoyl) sphingosine (NBD-C6Cer) and N-
(4,4,-difluoro-5-,7-dimethyl-bora-3a,4a-diaza-sindacene- 3-pentanoyl)sphingosine 
(BODIPY-C5Cer) were from Life Technologies (Italy). The antibodies recognizing 
Phospho-Akt (Ser473) were from Cell Signaling Technology, Inc. (Danvers, MA, USA); 
polyclonal antibodies against Cer transfer protein (CERT) from Bethyl Laboratories 
(Montgomery, TX, USA). Primary mouse monoclonal anti-phospho-serine, goat anti-
GRP78 and rabbit anti-GAPDH antibodies, and secondary HRP-conjugated anti-rabbit or 
anti-goat antibodies were from Santa Cruz Biotechnology (Santa Cruz, CA, USA). 
Secondary anti-mouse HRP-conjugated antibody, SuperSignal WestPico 
Chemioluminescent Substrate and SuperSignal WestFemto Maximum Sensitivity Substrate 
were from Thermo Scientific (Rockford, IL, USA). Ceramide/Sphingoid Internal Standard 
Mixture I from Avanti Polar Lipids (Alabaster, Alabama, USA) was used for quantitative 
analysis. The plasmid of CERT tagged with green fluorescent protein (CERT-GFP) was 
kindly provided by Dr. Maria Antonietta De Matteis, Telethon Institute of Genetics and 
Medicine, Napoli (Italy).  
 
Cell culture  
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Rat insulinoma INS-1 cells, provided by Merck–Serono, were grown in RPMI 1640 medium 
buffered with 10 mM Hepes containing 10% (v/v) FCS, 2 mM L-glutamine, 1 mM sodium 
pyruvate, 50 μM 2-mercaptoethanol and 100 units/ml penicillin/streptomycin at 37 °C in an 
atmosphere of 5% CO2 and 95% humidified air. Before each experiment, INS-1cells were 
plated at 2×10
5
 cell/cm
2
 ,cultured for 24 h in RPMI 1640 plus 10% FCS and  then cultured 
in the presence of 5 mM or 30 mM glucose with or without 0.4 mM palmitate for 12 h; Cells 
incubation with 30 mM glucose and 0.4 mM palmitate mimics glucolipotoxicity conditions. 
When indicated, the cells were preincubated with 20µM LY294002, or 10 nM Wm or 0.1 
nM Tg for 30 min. Palmitate was resuspended in ethanol and dissolved in PBS containing 
5% (w/v) BSA free fatty acid (FFA) to obtain a 4 mM stock solution. The palmitate/BSA 
FFA stock solutions were diluted in RPMI 1640 medium supplemented with 1% FCS to 
obtain a 0.4 mM final concentration [101]. 
 
Analysis of cell viability 
Cell viability was measured by MTT assay. MTT (3-[4,5-dimethylthiazol-2-yl]-2,5- 
diphenyltetrazolium bromide; thiazolyl blue) is a water soluble tetrazolium salt. Dissolved 
MTT is converted to an insoluble purple formazan by cleavage of the tetrazolium ring by 
dehydrogenase enzymes. This water insoluble formazan can be solubilized using solvents 
and the dissolved material is measured spectrophotometrically yielding absorbance as a 
function of concentration of converted dye. INS-1 cells were plated and cultured in the 
presence of 5 mM or 30 mM glucose with or without 0.4 mM palmitate for 12 h, as 
previously described, or for 24 hours. At the end of the treatments, the medium was replaced 
by MTT dissolved in fresh medium (0.8 mg/ml) for 4 hours. The formazan crystals were 
then solubilized in isopropanol/formic acid (95:5 v/v) for 10 minutes and the absorbance 
(570 nm) was measured using a microplate reader (Wallack Multilabel Counter, Perkin 
Elmer, Boston, MA, USA) [101]. 
 
RNA interference 
INS-1 cells were transfected with siRNA duplexes for rat CERT (Gene accession number 
XM 345143.1) using LipofectAMINE 2000according to the manufacturer’s protocol.  S87, 
S522 and control non-targeting siRNAs (scrambled sequences of S87 and S522 
oligonucleotides) described in [11] were used. We used Stealth RNAi, the chemically 
modified synthetic RNAi duplexes that virtually eliminate the induction of non-specific 
cellular stress response, and that improve the specific, effective knockdown of gene 
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expression. INS-1 cells plated at 2x10
5
 cell/cm
2
 were maintained for 24 h in RPMI 1640 
plus 10% FCS and then transfected in the same medium with a 1:1 (by mol) mix of S87 + 
S522 (si-CERT) or the non-targeting corresponding sequences (si-CT)  . The final 
concentration of siRNA–lipofectamine duplex mixture was 100 nM. All the experiments 
were performed 72 h after transfection [101]. 
 
Plasmid Transfection 
INS-1 cells were plated at 2×10
5
 cell/cm
2
 on a glass coverslip and grown in RPMI 1640 
supplemented with 10% FCS until they were 50–70% confluent. Then cells were transfected 
with expression plasmid encoding the protein CERT tagged with GFP (CERT-GFP) or 
pcDNA3.1 empty vector using the Lipofectamine 2000 reagent according to the 
manufacturer’s directions [101].  
 
[
3
H]Sphingosine metabolism 
INS-1 cells and INS-1 cells siCT and siCERT plated at 2×10
5
 cell/cm
2 
were cultured in the 
presence of 5 mM or 30 mM glucose with or without 0.4 mM palmitate for 12 h. Then cells 
were pulsed with [
3
H]Sph (0.3µCi/ml) for 1 h at 37°C. Stock solutions of [
3
H]Sph were 
prepared in absolute ethanol and added to fresh medium. In all cases, the final concentration 
of ethanol never exceeded 0.1% (v/v). At the end of pulse, cells were washed twice with 
phosphate-buffered saline (PBS) at 4°C, harvested and submitted to lipid extraction and 
partitioning as previously described [102]. The methanolized organic phase and the aqueous 
phase were analyzed by HPTLC using chloroform/methanol/water (55:20:3 by vol) and 
chloroform/methanol/0.2% CaCl2 (55:45:10 by vol) as solvent system respectively. Digital 
autoradiography of HPTLC plates was performed with Beta-Imager 2000 (Biospace, France) 
and the radioactivity associated with individual lipids was measured using the software 
provided with the instrument [101]. The [
3
H]-labeled sphingolipids were recognized and 
identified as previously described [102]. 
 
Liquid chromatography-tandem mass spectrometry (LC-MS/MS) protocol for lipid 
extraction and quantitation 
Cellular lipids were extracted from INS-1 cells according to Shaner et al. [103] with 
modifications. Briefly, freeze-dried INS-1 cells (2 million) were transferred to a 5 ml glass 
tube, spiked with 10 μl of internal standard (12.5 μM Ceramide/Sphingoid Internal Mix I), 
and extracted with 2 ml of chloroform:methanol (1:2, v/v) following brief sonication and 
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constant agitation in a 50°C water bath for 2 h. After cooling to room temperature, 200 µl of 
1M KOH in methanol were added and incubated for 2 h at 37ºC. After cooling, 15 µl of 
glacial acetic acid were added to neutralize the extract. Following centrifugation, the 
supernatant was transferred to a new glass tube and the extraction was repeated with a 
further 2 ml of chloroform:methanol (1:2, v/v). The resulting supernatants were pooled and 
dried under a stream of N2. The lipids were resuspended in 200 µl of mobile phase (mobile 
phase A: mobile phase B, 1:1, v/v). After centrifugation, aliquots were used for LC-MS 
analysis. Inorganic phosphate (Pi) content of extracts were determined according to van 
Veldhoven and Mannaerts [104].  Peak areas were used for quantitation by comparison with 
the peak areas of internal standards. 
Chromatographic separation of lipids was performed with an HPLC system consisting of a 
binary pump, auto sampler, column oven (1200 RRLC, Agilent Technologies, 
http://www.chem.agilent.com). The lipid molecules were separated using a GeminiNX C18 
analytical column (2.0 mm I.D. x 100 mm, particle size 3 µm, Phenomenex, 
http://www.phenomenex.com). Column oven and auto sampler temperatures were 
maintained at 45C and 4C, respectively. The mobile phase consists of solvent A (15 mM 
ammonium formate (pH 4.0):MeOH:THF, 5:2:3) and solvent B (15 mM ammonium formate 
(pH 4.0):MeOH:THF, 1:2:7). Elution was performed at a flow rate of 0.30 ml min
-1
 in a 
binary gradient mode. The initial composition of mobile phase was 65:35 (A:B), linearly 
changed to 70:30 (A:B) over 12 min, and maintained this composition over 22 min, changed 
to initial composition 65:35 (A:B) over 1 min, followed by 7 min of column re-equilibration. 
Column eluant was directed to waste for the initial 1 min.  
The HPLC system was coupled online to an Agilent 6460 triple quadrupole mass 
spectrometer (Agilent Technologies) equipped with a Jet Stream ion source. Data were 
recorded in positive ionization mode using electrospray ionization with nitrogen as the 
nebulizing gas. The gas temperature and flow rate was 350C and 10 l min-1, and the sheath 
gas temperature and flow rate was 360C and 12 l min-1, respectively. The ESI needle 
voltage was adjusted to 4000V in positive mode and optimum fragmentor voltages and 
collision energies were assigned by analysis of reference compounds (SM (d18:0/12:0); Cer 
(d18:1/12:0); GlcCer (d18:1/12:0); S1P (d18:1-P))  in selected ion and product ion scanning 
mode to determine multiple-reaction monitoring (MRM) conditions and mass spectrometric 
structural studies. MRM detection was applied using nitrogen as the collision gas [101].  
 
Analysis of the Intracellular Distribution of Fluorescent Ceramides 
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INS-1 cells were plated and grown on a glass coverslip and cultured as previously described. 
At the end of the treatments, the cells were loaded with 2.5 µM BODIPY-C5-Cer or NBD-
C6-Cer (as 1:1 complex with fatty acid free BSA) in RPMI 1640 at 4 °C for 30 min [11]. 
After loading, the cells were incubated 30 min at 37 °C in RPMI 1640 containing 5 mM or 
30 mM glucose in the presence or absence of 0.4 mM palmitate and fixed with 0.5% 
glutaraldehyde solution in PBS for 10 min at 4 °C. The specimens were immediately 
observed and analyzed with a fluorescence microscope (Olympus BX-50) equipped with a 
fast high resolution charge-coupled device camera (Colorview 12) and an image analytical 
software (Analysis from Soft Imaging System GmbH) [101]. 
 
Analysis of intracellular localization  of CERT-GFP by Cconfocal microscopy 
INS-1 cells plated at 2×10
5
 cell/cm
2
 were grown on a glass coverslip and maintained 24 h in 
RPMI 1640 plus 10% FCS. The cells were then transfected with the plasmid, CERT-GFP 
using lipofectamine 2000 according to manufacturer’s instructions. 24 h after transfection, 
cells were treated with 5 mM or 30 mM glucose ± 0.4 mM palmitate for 12 h and fixed with 
0.5% glutaraldehyde solution in PBS for 10 min at 4 °C. The cells were then permeabilized 
with 0.2% Triton X-100 for 30 min at room temperature and stained with WGA-texas red. 
The specimens were analyzed with a confocal microscope (Leica SP5) [101]. 
 
Immunoblotting 
Phosho-Akt and GRP78 immunoblotting were performed on INS-1 cells lysed with lysis 
buffer (20mM Tris-HCl pH 7.4, 150 mM NaCl, 1% NP-40, 10 mM sodium fluoride, 1mM 
EDTA, 10mM Na4P2O7, 1mM Na3VO4, and the protease inhibitor cocktail). Solubilized 
proteins were centrifuged at 14000xg at 4 °C for 10 min. Supernatants were subjected to 
10% SDS polyacrylamide gel electrophoresis and transferred to nitrocellulose membranes. 
Membranes were blocked for 1 h at room temperature in Tris-buffered saline (10 mM Tris-
HCl, pH 7.4, 140 mM NaCl) containing 0.1% Tween-20 (TBS-T) and 5% skim milk, and 
then incubated with primary antibodies against phosho-Akt overnight at 4°C or against 
GRP78 1 h at room temperature. Membranes were washed in TBS-T, and bound antibodies 
visualized with horseradish peroxidase-coupled secondary antibodies (Santa Cruz 
Biotechnology) and chemiluminescent substrate. The relative intensities of bands were 
quantified by densitometry. 
CERT immunoblotting were performed using wild type or si-CT and si-CERT transfected 
cells lysed with CERT buffer (10mM Tris-HCl pH 7.4, 0.25mM sucrose, 0.5mM 
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phenylmethylsulfonyl fluoride, 10µg/ml aprotinin, 5µg/mL leupeptin, 5µg/mL pepstatin), 
processed and analyzed as previously described [11]. The membranes were stripped 30 
minutes at 50°C in 2% SDS, 100mM DTT, 0.5M Tris-HCl pH 6.8, washed in TBS-T and 
incubated 1 hour in Tris-buffered saline (10 mM Tris-HCl, pH 7.4, 140 mM NaCl) 
containing 0.1% Tween-20 (TBS-T) and 5% BSA and then incubated with the primary 
antibody against phospho-serine 2 h at room temperature. Membranes were washed in TBS-
T and bound antibodies visualized with horseradish peroxidase-coupled secondary 
antibodies (Santa Cruz Biotechnology) and chemiluminescent substrate [101].  
 
RNA isolation, reverse transcription and Real-Time PCR 
INS-1 cells were plated and grown on a glass coverslip and cultured as previously described. 
At the end of the treatments, total RNA was isolated from INS-1 cells with the RNeasy mini 
kit and treated with the RNase-free DNAse I. One microgram of RNA was reverse 
transcribed using the iScript cDNA synthesis kit according to manufacturer’s instructions. 
Real-Time PCR was performed using the iQ5 Real-Time PCR detection system (Biorad 
Laboratories, Hercules, CA, USA). Specific SYBR green expression assays (SYBR green 
super mix) for CERT and TBP (TATA-box-binding protein) were carried out. Simultaneous 
amplification of the target sequences was carried out as follows: 3 minutes at 95 °C, 50 
cycles 95°C 10 sec, 59 °C 40 sec and 60 °C 30 sec and 1 cycle of 60
 
°C 3 minutes. Results 
were analyzed using the iQ5 optical system software (Biorad Laboratories, Hercules, CA, 
USA). Relative gene expression was determined using the 2
-ΔΔCt
 method [105]. Data were 
normalized to TBP expression (used as endogenous control) and INS-1 G5 cells were used 
as calibrator [101]. 
 
Sphingomyelin synthase activity 
INS-1 cells were plated and treated as described above. At the end of the treatments, the 
cells were loaded with 2.5 µM NBD-C6-Cer (as 1:1 complex with fatty acid free BSA) in 
RPMI 1640 at 4 °C for 30 min. After loading, the cells were incubated 15 or 30 min at 37 °C 
in RPMI 1640 with 5mM glucose or 30 mM glucose ± 0.4 mM palmitate. At the end of the 
incubation, cells were immediately put at 4°C to stop the enzymatic reaction; lipids were 
extracted with chloroform -methanol [106] and separated by thin-layer chromatography 
(TLC) using chloroform/methanol/0.1M KCl (1:2:0.8 [vol/vol/vol]) as the developing 
solvent. Fluorescence-labeled sphingomyelin was quantified with a luminescence 
spectrometer (LS50B PerkinElmer) [101]. 
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Other methods 
Total protein amount was assayed with the Comassie Blue based Pierce reagent, using BSA 
fraction V as standard. Radioactivity was measured by liquid scintillation counting.  
 
Statistical analysis 
Statistical significance of differences was determined by one-way ANOVA. 
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RESULTS 
Effect of palmitate and glucose on cell viability and ER stress in INS-1 cells 
We first evaluated the effect of palmitate and glucose on cell survival and ER stress in INS-1 
cells. To this end, we treated cells for 12 hours with both 0.4 mM palmitate (P4) and 30 mM 
glucose (G30) alone and in coadministration (G30P4); our results demonstrated that not all 
treatments affected cell viability. (Fig. 1 left panel). After 24 hours of treatment with 
palmitate or 30 mM glucose we did not observe any toxic effects; G30 treatment determined 
an increase  of INS-1 cell as demonstrated in a previously paper [107]. On the contrary, in 
INS-1 cells, G30P4 treatment for 24 hours decreased cell viability by 53% (Fig. 1a right 
panel). 
 
 
Figure 1: Palmitate and glucose regulate cell viability in INS-1 cells. Cells were treated for 12 h 
(left panel) or 24 h (right panel) with 0.4 mM palmitate (P4) or without palmitate in the presence of 
5mM or 30mM glucose. Cell viability was assessed by MTT assay. Results are expressed as 
percentage of cell viability with respect to 5 mM glucose-treated cells (100%). Data are the mean ± 
S.D. of three independent experiments. *, p< 0.05; ** p< 0.01. 
 
Moreover, evaluation of GRP78 expression, an ER stress indicator, by Western blot, showed 
that 12 hours treatment with G30P4 induced about 60% increase in GRP78 levels compared 
to G5, G5P4, G30 conditions in INS-1 cells (Fig.2). These data suggested that 
glucolipotoxic conditions induced ER stress. We treated INS-1 cells with 0.1 M 
thapsigargin (Tg) in the presence of 5 mM glucose  to have a positive control with  an 
increased amount of GRP78 (Fig.2) [101]. 
 12h 24h 
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Figure 2: Palmitate and glucose regulate GRP78 expression in INS-1 cells. INS-1 cells were 
treated with 5 mM or with 30 mM glucose in the presence or not of 0.4 mM palmitate and harvested 
in lysis buffer for immunoblot analysis as described in experimental procedures. INS-1 cells were 
pretreated 30 min with or without 0.1 M thapsigargin (Tg). Equal amounts of protein from 
homogenates were analyzed by immunoblotting with an anti-GRP78 antibody and an anti-GAPDH 
antibody. 
 
Effect of palmitate and glucose on [
3
H]Sph metabolism in INS-1 cells 
We wanted to evaluate the effect of G30P4 treatment on Cer utilization for the biosynthesis 
of SM and GSLs in INS-1 cells. We used tritiated sphingosine as a metabolic precursor. In 
fact, [
3
H]Sph is rapidly bring inside the cells, efficiently N-acylated to Cer, which is 
transformed to SM and GlcCer and then to complex GSL. We executed short pulse 
experiments in order to observe the use of newly synthesized Cer for the biosynthesis of SM 
and GlcCer [12]. In all conditions studied, tritiated Sph was mainly processed into N-
acylated compounds:  Cer, SM and, in lower amounts, GSL (Fig.3); the levels of [
3
H]N-
acylated sphingolipids is similar in all treatments. In the presence of P4 the distribution of 
radioactivity between the different tritiated metabolites were significantly modified with 
respect to G5 treatment. In INS-1 cells P4 treatment induced [
3
H]Cer accumulation which 
was associated to a decrease of [
3
H]SM levels (Fig.3). G30 treatment also decrease [
3
H]Cer 
conversion to [
3
H]SM. Moreover, G30 treatment strongly increase the reduced utilization of 
Cer for SM biosynthesis induced by palmitate, and significantly reduced GSL biosynthesis 
(Fig.3). The percent increase of [
3
H]Cer was 23% and 14%, respectively in G5P4 and G30 
treated cells;  in G30P4 treated cells [
3
H]Cer was 54% higher (Fig.3) than in G5 treated 
cells. On the contrary, the reduction of [
3
H]SM was 32% and 23% in P4 or G30 treated cells 
and 64% in G30P4 treatment, demonstrating that glucolipotoxic condition has a greater 
effect than the sum of the individual treatments (palmitate or 30 mM glucose). Taken 
together, these results strongly support that in pancreatic cells, glucolipotoxicity can 
control the utilization of Cer for the biosynthesis of complex sphingolipids in the Golgi 
apparatus [101].  
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Figure 3: Palmitate and glucose regulate the use of Cer for the biosynthesis of complex 
sphingolipids in INS-1 cells. Cells were treated for 12 h with or without palmitate in the presence of 
5mM or 30mM glucose and then pulsed with 0.3 Ci/ml [C3-3H]Sphingosine for 1 h. At the end of 
pulse, cells were harvested and submitted to lipid extraction and partitioning. The methanolized 
organic phase and the aqueous phase were analyzed by HPTLC and digital autoradiography of 
HPTLC (see experimental procedures). G5, 5 mM glucose; G5P4, 5 mM glucose+0.4 mM palmitate; 
G30, 30 mM glucose; G30P4, 30 mM glucose+0.4 mM palmitate. Data are the mean  S.D. of at 
least three independent experiments. *p<0.05, **p <0.01 
 
Effect of palmitate and glucose on Cer, SM and GlcCer molecular species 
Next, we evaluated the levels of Cer, SM and GlcCer  and their molecular species by 
LC/MS/MS in INS-1 cells treated with palmitate. Our results showed that G5P4 as well as 
G30 treatments  did not significantly modify Cer, SM and GlcCer mass levels in INS-1 cells 
(Fig.4); Conversely, G30P4 condition  promoted an increase of Cer mass levels with a 
associated decrease in  the mass levels of SM but not that of GlcCer. Our data show that 
glucolipotoxic conditions induce an increase in saturated ceramides, mostly in C18:0-Cer 
and C22:0-Cer (Fig. 4). Moreover, this condition manly reduces the levels of saturated SM, 
specifically C18:0-SM and C24:0-SM (Fig.4).  
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Figure 4: Chain-length specificity of ceramide, sphingomyelin and glucosylceramide in 
response to palmitate and high concentrations of glucose in INS-1 cells. Cells were incubated 
with 0.4 mM palmitate in the presence of 5 mM (G5) or 30 mM (G30) glucose for 12 h. Levels of N-
acyl chain lengths of Cer (a), SM  (b)and GlcCer (c) were determined by LC–MS/MS. Levels of S1P 
in INS-1 cells were also determined by LC-MS/MS measurement (d). Results are expressed as 
pmol/nmol of phospholipids (PL) for Cer and SM and as fmol/nmol PL for GlcCer and S1P and are 
means  S.D. for three independent experiments. *p <0.05 vs G5 except for S1P *p <0.05 vs G30. 
 
On the contrary, glucolipotoxicity condition did not alter significantly the levels of the 
different GlcCer molecular species (Fig.4). We also evaluated the levels of S1P in INS-1 
cells treated with palmitate. Our data showed that G5P4 treatment did not increase 
significantly S1P levels in INS-1 cells. However, after a 12 hours of G30P4 treatment  S1P 
SM 
S1P 
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levels were considerably increased (Fig.4), in agreement with data obtained by Verét et al. 
[108]. 
Altogether, these data suggest that glucolipotoxicity increased Cer levels and decreased SM 
levels in pancreatic -cells, but did not appear significantly affect the amounts of GlcCer 
[101].  
 
Effect of palmitate and glucose on Sphingomyelin Synthases activity 
We wanted to evaluate if the decrease observed in SM levels induced by glucolipotoxicity 
could be due to the inhibition of SMS activity. To this end, we used the NBD-C6-Cer, a 
fluorescently labeled Cer that is a good substrate for SM synthases. G5P4 or G30P4 
treatments demonstrated that the activity of SMS in INS-1 cells was not altered (data not 
shown), suggesting that the enzymes activities involved in the biosynthesis of SM were not 
affected by glucolipotoxic conditions in INS-1 cells [101]. 
 
Effect of palmitate and glucose on intracellular distribution of BODIPY-C5Cer and 
NBD-C6Cer 
We then evaluated if the glucolipotoxicity can affect the Cer transport from the ER to Golgi 
apparatus (where SM and GSL biosynthesis occurs). To follow the movement of 
endogenous Cer from the ER to the Golgi apparatus we studied BODIPY-C5-Cer 
redistribution in cells [106]. In INS-1 cells, G5 and G30 treatments showed most of the 
fluorescence localized in the perinuclear region (Fig.5a), representative of the Golgi 
apparatus. In INS-1 cells, G5P4 treatment induces fluorescence accumulation in the 
perinuclear region in a lesser extent compared to control cell, suggesting a deficit in Cer 
traffic (Fig. 5a). 
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Figure 5: Palmitate and glucose impairs ceramide flow from the ER to the Golgi apparatus in 
INS-1 cells. INS-1 cells grown on a glass coverslip were pretreated 30 min with or without 0.1 M 
thapsigargin. At the end of the pretreatment, the cells were treated with or without palmitate in the 
presence of 5 mM or 30 mM glucose for 12 h and then incubated with a) 2.5 M BODIPY-C5Cer or 
b) 2.5 M NBD-C6Cer as BSA complex 1:1 (m/m) in DMEM for 30 min at 4 °C; labeled cells were 
incubated at 37 °C for 30 min and analyzed. All images were processed and printed identically.  
 
 
 
 
a) 
b) 
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Glucolipotoxic condition (G30P4) determines a strong reduction of fluorescence 
accumulation in the Golgi apparatus (Fig.5a), supporting an impairment of Cer flow from 
the ER to the Golgi apparatus. In INS-1 cells, Tg, which is an  ER stress activator in -cells 
(Fig.2) [98], has the same effect of G30P4 treatment, strongly reducing the fluorescence 
staining at the Golgi apparatus (Fig.5a).  The effect of Tg was not modified in the presence 
of glucose or palmitate. In contrast, in INS-1cells labeled with NBD-C6Cer, which rapidly 
stain the Golgi apparatus [106], 5 mM and 30 mM glucose in the presence or not of 0.4 mM 
palmitate with or without Tg did not modify the accumulation of NBD fluorescence in the 
perinuclear Golgi region (Fig. 5b). Altogether, these results suggest that glucolipotoxicity 
induces an impairment of Cer flow from the ER to the Golgi apparatus in pancreatic -cells 
[101]. 
 
Effect of palmitate and glucose on CERT expression and phosphorylation 
Recent findings suggest that in INS-1 cells, long-term treatment (48 h) with palmitate inhibit 
CERT-mediated Cer transport modifying the repression of pro-insulin gene expression 
[109]. On these premises, we evaluated if a shorter treatment (12 h) of INS-1 cells with 
palmitate and glucose can modify the levels and the activation status of the protein CERT. 
Western blot analysis demonstrated that both 0.4 mM palmitate or 30 mM glucose alone did 
not significantly alter the expression of the CERT protein (Fig.6) whereas cotreatment with 
0.4 mM palmitate and 30 mM glucose induced a 65% reduction in the total amount of CERT 
in INS-1 cells (Fig.6). Moreover, in order to evaluate the amount of phosphorylated CERT, 
we used an antibody against phospho-serine according to Guo [109]. We found that 
palmitate or 30 mM glucose alone did not modify significantly the amount of phospho-
CERT. Interestingly, coadministration of 0.4 mM palmitate and 30 mM glucose doubled the 
levels of phospho-CERT in INS-1 cells (Fig.6).  
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Figure 6: Palmitate and glucose regulate CERT expression and activation in INS-1 cells. a) 
INS-1 cells were harvested in lysis buffer as described in material and methods. Equal amounts of 
protein from homogenates were analyzed by immunoblotting with an anti-CERT antibody, an anti-
phosphoserine and an anti-GAPDH antibody; b) the amount of CERT expressed was determined by 
densitometric quantitation and normalized for GAPDH **p <0.01 for G30+palmitate compared with 
G30; c) the amount of pCERT expressed was determined by densitometric quantitation and 
normalized for CERT **p <0.01 for G30+palmitate compared with G30; d) Relative expression of 
CERT assessed by Real-Time PCR. Results are expressed as fold-change relative to G5 *p < 0.05 
G30+palmitate cells vs G30. Values are mean ± SD of three independent experiments. 
 
In order to assess if palmitate regulates CERT expression at the transcriptional level, CERT 
expression was evaluated by Real-Time PCR assay in INS-1 cells. The results obtained (Fig. 
6d) show that palmitate in the presence of 30 mM glucose induced a reduction of 80% of 
CERT expression, thus demonstrating that glucolipotoxicity regulates CERT expression 
[101]. 
 
a) b) 
c) d) 
G30P4 
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Effect of palmitate and glucose on CERT subcellular localization 
The phosphorylated form of CERT should have the docking site for the Golgi apparatus 
covered by the START domain. In this conformation, CERT should not be able to colocalize 
with the Golgi apparatus [110]. To this end, we evaluated the ability of CERT to localize at 
the Golgi apparatus in INS-1 cells. We analysed the co-localization of over-expressed 
CERT-GFP with the Golgi marker WGA in INS-1 cells. The images obtained (Fig.7a) 
showed that in INS-1 cells treated with 5 mM glucose in the presence or the absence of 0.4 
mM palmitate, or treated with 30 mM glucose, CERT and WGA co-localized. In contrast, 
co-treatment with 30 mM glucose and 0.4 mM palmitate significantly reduced co-
localization between CERT and WGA in INS-1 cells (Fig.7a) according to the Pearson’s 
colocalization coefficients (Fig.7b). Moreover, when INS-1 cells were treated with 5 mM 
glucose in the presence or absence of 0.4 mM palmitate, or treated with 30 mM glucose 
alone, CERT and WGA colocalize in more than 90% of the cells analysed (Fig.7c). On the 
contrary, in cells treated with 30 mM glucose in the presence of 0.4 mM palmitate the 
colocalization of CERT and WGA was detectable in only 8% of the cells (Fig.7c). 
Altogether, our results (Fig.6 and 7) demonstrated that glucolipotoxicity impair CERT-
mediated Cer transport by reducing both CERT levels and CERT activity through its 
phosphorylation, a condition that reduces the capacity of CERT to bind Cer and prevent its 
localization to the Golgi apparatus [101]. 
 
a) 
b) 
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Figure 7: Palmitate and glucose prevent colocalization of CERT and Golgi apparatus in INS-1 
cells. INS-1 cells grown on a glass coverslip were transfected with the plasmid CERT-GFP as 
described in experimental procedures. 24 h later, the cells were treated with or without palmitate in 
the presence of 5 mM or 30 mM glucose for 12 h. Cells were then fixed and immunostained with 
WGA texas red-conjugated, a specific marker for the Golgi apparatus. a) Representative confocal 
microscopy images are shown; all images were processed identically. b) The colocalization between 
CERT and WGA has been quantified through the software Image J and reported as Pearson 
colocalization coefficient c) The percentage of cells with colocalization of CERT and WGA was 
determined. The data are means ± the SD. *p<0.005 
 
Effect of palmitate and glucose on [
3
H]Sph metabolism in INS-1 cells silenced for 
CERT 
Based on the results obtained, we next evaluated if CERT depletion could mimic the defect 
in Cer utilization induced by glucolipotoxicity. To this purpose, we studied the effect of 
palmitate with high glucose (30 mM) on [
3
H]Sph metabolism in control and CERT-down-
regulated INS-1 cells. The condition of CERT silencing determines a ≥90% reduction in 
CERT expression when cells were transfected with a mixture of S87 and S522 (1:1 ratio), as 
shown in the immunoblot in fig.8a.  
c) 
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Figure 8: Palmitate and glucose affect vesicular-mediated Cer transport. a) Cells were 
transfected with siRNA for CERT (siCERT) and the corresponding non-targeting corresponding 
sequences as control (siCT) and 72 h after transfection harvested in lysis buffer. The same amount  
from homogenate fractions and recombinant CERT (CERT) were analyzed by immunoblotting with 
polyclonal antibody anti-CERT and monoclonal anti-GAPDH. b) INS-1 cells downregulated for 
CERT were treated for 12 h with or without palmitate in the presence of 30 mM glucose. Then the 
cells were pulsed with 0.3 Ci/ml [C3-3H]Sphingosine for 1 h and processed and analyzed as 
described in the legend of fig. 3. Data are mean  S.D. of at least three independent experiments. 
*p<0.05; **p <0.1.  
 
As expected, down regulation of CERT promoted a significant but not complete reduction of 
[
3
H]Cer conversion to [
3
H]SM without modifying the amount of synthesized [
3
H]GSL (Fig. 
8b). Palmitate together with 30 mM glucose decreased [
3
H]Cer utilization for the synthesis 
of [
3
H]SM and [
3
H]GSL in control cells (siCT) but also in siCERT ones (Fig. 8b). In 
particular, our results demonstrated that glucolipotoxicity induced a 52% decrease of 
[
3
H]SM in siCT cells and 65% in siCERT cells compared to cells treated with 30 mM 
glucose in the absence of palmitate. These results suggest that glucolipotoxicity, in addition 
to its effect on CERT-mediated Cer transport, can also affect vesicular-mediated Cer 
transport in pancreatic -cells [101].  
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Effect of PI3K/Akt on [
3
H]Sph metabolism in INS-1 cells treated with palmitate and 
glucose 
We previously demonstrated [18] that the PI3K/Akt pathway regulates the Cer vesicular 
traffic in glioma cells, so we determined if this occurs in INS-1 cells. Based on the literature, 
we first evaluated if a 12 h treatment with palmitate and high glucose levels was able to 
regulate the PI3K/Akt pathway in INS-1 cells. Western blot analysis with a specific antibody 
for Akt phosphorylated at Ser473, demonstrated that 30 mM glucose did not modify pAkt 
levels, but 0.4 mM palmitate alone decreased pAkt levels and 0.4 mM palmitate together 
with 30 mM glucose induced a marked decrease of pAkt levels in INS-1 (Fig. 9). 
 
 
Figure 9: Palmitate and glucose inhibit  PI3K/Akt pathway. INS-1 cells were treated with 5 mM 
or with 30 mM glucose in the presence or not of 0.4 mM palmitate and harvested for immunoblot 
analysis of phospho-Akt and GAPDH levels as described in experimental procedures. 
 
To investigate the effect of PI3K/Akt on Cer metabolism in INS-1 cells, we utilized 
LY294002, an inhibitor of PI3K. We initially set up working concentrations to specifically 
inhibit PI3K/Akt. To this purpose, we evaluated the ability of LY294002 and Wm to inhibit 
the PI3K/Akt pathway. Immunoblot analysis demonstrated that both 20 M LY294002 and 
10 nM Wm strongly reduced Akt activation (data not shown). INS-1 cells, treated with 5 
mM or 30 mM glucose with or without palmitate, were pulsed with [
3
H]Sph in the presence 
or absence of LY294002 or Wm and the PI3K inhibitors did not alter the [
3
H]Sph uptake, 
determined as the radioactivity amount in the total lipid extract (data not shown). In all 
cases, [
3
H]Sph was mainly metabolized to N-acylated compounds (Fig.10 a-d) and the 
extent of N-acylation (evaluated as the sum of tritiated Cer, SM and GSL) was always very 
similar in the control and treated cells. However, treatment with LY294002 or Wm strongly 
modified the radioactivity distribution among the different Sph metabolites both in the 
presence of 5 mM or 30 mM glucose (Fig.10 a and 10 b). In 5 mM glucose plus LY294002 
or 5 mM glucose plus Wm treated INS-1 cells, the radioactivity associated to [
3
H]Cer was 
respectively 21% and 17% higher than that in 5 mM treated cells, with a concomitant 
reduction of both [
3
H]SM and [
3
H]GSL levels. In particular, [
3
H] SM was 39% and 32% 
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lower respectively in the presence of LY294002 and Wm, whereas [
3
H]GSL were 29% and 
27% lower, respectively in the presence of LY294002 and Wm compared to 5 mM treated 
cells (Fig.10a).  
 
 
Figure 10: Palmitate and glucose inhibit vesicular-mediated Cer traffic a) INS-1 cells were 
treated for 12 h with 5 mM glucose in the presence or absence of LY294002 or of Wm; b) INS-1 
cells were treated for 12 h with 30 mM glucose in the presence or absence of LY294002 or Wm; c) 
INS-1 cells were treated for 12 h with 5 mM glucose plus 0.4 mM palmitate  in the presence or 
absence of LY294002 or Wm;  d) treated for 12 h with 30 mM glucose plus 0.4 mM palmitate in the 
presence or absence of LY294002 or Wm. Then cells were pulsed 1 h with [
3
H]Sph in the absence 
(opened and dotted bars)  or presence of 20M LY294002 (striped bars) or 10 nM Wm (square 
bars). At the end of pulse, cells were harvested and submitted to lipid extraction and analyzed as 
described in the legend of fig. 3. All values are the mean + S.D. of at least three individual 
experiments. *p<0.05, **p <0.01. 
 
Similarly, in cells treated with 30 mM glucose, LY294002 and Wm promoted about 30% 
reductions in synthesized [
3
H]SM and 20% decrease in [
3
H]GSL compared to 30 mM 
glucose treated cells (Fig.10 b). Taken together these results suggest that the PI3K/Akt 
pathway can regulate the metabolic utilization of Cer through the modulation of the 
a) b) 
c) d) 
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vesicular traffic of Cer, favouring the maintenance of low Cer levels in INS-1 cells even in 
conditions (high glucose) of reduced utilization of Cer for the biosynthesis of complex 
sphingolipids. In cells treated with 5 mM glucose+palmitate, LY294002 or Wm slightly 
reduced the amount of synthesized SM and GSL (Fig.10 c). In G30P4 treated cells 
(characterized by a reduced utilization of Cer for the biosynthesis of complex sphingolipids), 
LY294002 or Wm did not further reduce the amount of synthesized SM and GSL (Fig.10 d). 
Altogether, this data suggest that palmitate inhibits vesicular-mediated Cer traffic through 
downregulation of PI3K/Akt pathway. This effect is strongly potentiated in glucolipotoxic 
conditions, thereby contributing to the accumulation of Cer in pancreatic -cells [101]. 
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DISCUSSION 
Based on different approaches using a tritiated precursor and fluorescent analogs of Cer, this 
study  provides evidence that, in INS-1 cells, elevated glucose and fatty acid levels affect 
Cer traffic from the ER to the Golgi apparatus, promoting Cer accumulation in the ER. In 
particular, 12 hours of glucolipotoxic treatments reduce Cer utilization for the biosynthesis 
of SM, GlcCer and complex GSL. We demonstrated that, consequently, Cer levels increase 
whereas total SM but not GlcCer levels decrease. Interestingly, glucolipotoxicity modified 
only saturated SM species in -cells, thus leading to the accumulation of saturated Cer 
species such as C18:0-Cer, which are known mediator of apoptosis in -cells [107].  The 
reduction of SM biosynthesis was not due to a possible effect of glucolipotoxicity on SMS 
activity in the Golgi apparatus. In fact, under glucolipotoxic condition, using the SMS 
substrate NBD-C6-Cer, which reaches the Golgi apparatus by easy diffusion through the 
cytosol, we established that INS-1 cells maintained the ability to properly synthesize SM. 
On the other hand, in the same experimental conditions, the analysis of intracellular 
distribution of BODIPY-C5-Cer, which employs the same transport mechanisms of natural 
Cer [12, 106, 112], demonstrated a defect in the Cer intracellular traffic from the ER to the 
Golgi apparatus. These data support that in glucolipotoxic conditions, this mechanism can 
contribute to Cer accumulation at the ER. Moreover, several recent studies have 
demonstrated that palmitate–dependent accumulation of Cer at the ER is associated to ER 
stress induction and apoptosis of pancreatic -cells [98, 106, 113, 114]. In agreement with 
these observations,  our data demonstrated that 12 h of treatment with palmitate and high 
glucose concentrations induce ER stress in INS-1 cells,  underling the crucial role of Cer 
accumulation in the ER as a mechanism to promote -cells apoptosis, thus contributing to 
the development of type 2 diabetes [101]. As previously discussed, in INS-1 cells too, two 
main mechanisms operate to transport Cer from the ER to the Golgi apparatus: a CERT-
dependent and a CERT-independent system; we demonstrated that glucolipotoxicity 
strongly affected both of them. In particular, we observed a significant decrease in the total 
amount of CERT protein as well as in the mRNA level [101]. In this respect, Granero et al. 
identified a human-specific TNF-responsive promoter for CERT [116] involved in the 
transcriptional CERT regulation. Moreover, we demonstrated that, in glucolipotoxic 
conditions, the remaining CERT protein is in a highly phosphorylated status that impairs the 
correct recognition and localization to the Golgi apparatus of the CERT PH domain, 
strongly limiting CERT transfer activity [110]. Altogether, these data demonstrate that 
glucolipotoxicity impairs the CERT-mediated Cer traffic from the ER to the Golgi 
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apparatus, thus supporting that, under glucolipotoxic conditions, this mechanism contributes 
to the accumulation of Cer at the ER.  
The vesicle-mediated CERT-independent Cer transport was also impaired under 
glucolipotoxic condition. In fact, in INS-1 cells silenced for CERT, glucolipotoxicity is still 
able to reduce the metabolic utilization of Cer for the synthesis of SM and GSL. In INS-1 
cells, the PI3K/Akt pathway is involved in the positive regulation of Cer metabolism [101], 
as demonstrated also in glioma cells [18]. Glucolipotoxicity promotes a strong inhibition of 
Akt, consistent with previous studies showing that long-term exposure to glucolipotoxic 
conditions and/or high palmitate decreases Akt activation in pancreatic -cells [117-119]. 
Also palmitate alone partially decreased pAkt levels and this was associated to the inhibition 
of Cer vesicular traffic. 
Moreover, our results demonstrated that glucolipotoxicity increased total S1P levels in INS-
1 cells. Giussani et al. [115] demonstrated that the decrease of S1P is associated to a Cer 
traffic impairment; in addition, in the second part of this thesis, we demonstrated that S1P 
promotes Cer vesicular transport from the ER to the Golgi apparatus. This lead us to 
hypothesize that increased S1P levels are not sufficient to counteract the effect of 
glucolipotoxicity on  Cer traffic [101].  
The PI3K inhibitors, LY294002 and Wortmannin, which are not effective in glucolipotoxic 
conditions, have a slight  effect on Cer flow in cells treated with palmitate in the presence of 
5 mM glucose, probably because palmitate alone partially inhibits pAkt. The results of our 
study support the idea that glucolipotoxicity inhibits the PI3K/Akt pathway in INS-1 cells, 
which in turn could inhibit Cer vesicular trafficking [101]. On the other hand, we 
demonstrated that 30 mM glucose decreases the biosynthesis of SM but does not modify 
pAkt levels and Cer traffic suggesting that in this case the effect on SM could be associated 
with increased N-SMase activity, consistent with previous papers [113, 120] wich 
demonstrate that high glucose levels increased N-SMase activity. Thus, in glucolipotoxic 
conditions we cannot exclude a contribution of this pathway to the decrease of SM levels. 
Altogether, our data demonstrate that the two Cer  transport mechanisms  can separately 
contribute to the control of sphingolipid metabolism and Cer levels in INS-1 cells [101], 
thus participating in the regulation of Cer accumulation in the ER involved in pancreatic -
cell function and death during T2D [98, 114]. Moreover,  these findings suggest that an 
impairment in ER to Golgi Cer traffic can act synergistically with enhanced de novo Cer 
biosynthesis [107, 121], leading to accumulation of Cer in the ER in response to 
glucolipotoxicity.  
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Further information on the mechanisms that regulate the accumulation of Cer at the ER will 
be important to develop new strategies to prevent T2D. Moreover, the capacity of the 
PI3K/Akt pathway to regulate sphingolipid metabolism may also be pathologically relevant 
in cells if we consider that the PI3K/Akt pathway plays a crucial role in the control of -
cell mass and function by modulating a dynamic balance of proliferation, cell size and 
apoptosis [122]. 
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Part 2: The stimulation of Ceramide traffic from 
the ER to the Golgi apparatus S1P-dependent as a 
survival factor in T98G glioma cells 
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INTRODUCTION 
 
Glioblastoma 
GBM is the most common malignant primary brain tumor in adults and one of the most 
lethal human cancers. Furthermore, GBM is characterized by elevated resistant to radiation 
and cytotoxic chemotherapy [123], with a median survival ranging from nine to twelve 
months [124, 125] despite aggressive surgical resection and conventional therapy [126]. The 
surgical approach often cannot be applied without functional loss of large areas of central 
nervous tissue with severe neurological impairment [123]. GBMs are part of the spectrum of 
malignant gliomas, which are thought to arise from the intrinsic glial cells of the brain [127]. 
Gliomas include a group of highly heterogeneous cancers classified, according to cell line 
derivation and differentiation morphological evidence, in astrocytoma, oligodendroglioma, 
oligoastrocytoma, ependymoma and choroid plexus tumours [124]. Astrocytomas are the 
highest incidence gliomas (75% of all gliomas) [128], sorted by the World Health 
Organization (WHO) in different classes, distinguished by the presence of specific 
histological characteristics such as nuclear atypia, mitotic activity, endothelial proliferation 
and necrosis [129]. In particular, it is possible to distinguish four different classes of 
astrocytomas: pilocytic astrocytoma (grade I), diffuse or fibrillary astrocytoma (grade II), 
anaplastic astrocytoma (Grade III), and glioblastoma multiforme (grade IV). The tumours 
belonging to the class I and II are considered with low-grade malignancy, while those of III 
and IV class are considered to be high-grade malignant [129]. Glioblastoma multiforme or 
simply glioblastoma (GBM) (WHO grade IV) is the most frequent malignant primary brain 
tumour and it is one of the most aggressive cancer.  
As defined by the term “multiforme”, GBM comprises morphologically heterogeneous 
neoplasms, in which the cellular composition can be highly variable. GBM is characterized 
by uncontrolled cell proliferation, diffuse infiltration, massive angiogenesis, high genomic 
instability, strong resistance to apoptosis and then to radio-chemotherapy, all distinguishing 
features representing useful prognostic factors for overall survival [126, 127, 130].  
Two classes of GBM have been identified: primary GBM (or GBM de novo) and secondary 
GMB [124]. Primary GBM accounts for about 90% of GBM cases and it is diagnosed 
without evidence of a previous lower-grade tumour. Primary GBM generally occurs in 
elderly patients (60-70 years old) and it is characterized by a very short clinical history (less 
than 3 months). On the other hand, secondary GBM, representing the minority of GBM 
cases, derives from a lower-grade tumour that undergoes the process of tumour progression 
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to higher malignancy grades. Secondary GBM usually occurs in adults between fifty and 
sixty years, and the time of progression from lower to higher degree of malignancy ranges 
from months to decades [130, 131]. 
 
Altered signalling pathways in glioblastoma tumorigenesis 
GBM has been selected to be profiled by the National Institutes of Health’s Cancer Genome 
Atlas (TCGA) and now it is one of the most molecularly profiled of all human tumors. 
TCGA and those of other groups [132], have defined that molecular alterations of GBM  
area characterized by amplification of EGFR, MET, platelet-derived growth factor receptor 
A (PDGFRA), MDM4, MDM2, CCND2, and phosphatidylinositol-4,5-bisphosphate 3-kinase 
A (PIK3CA), among others, and deletion of cyclin-dependent kinase inhibitor 2A/B 
(CDKN2A/B), CDKN2C, PTEN, retinoblastoma protein 1 (RB1), and NFKB1A. Somatic 
mutations of p53, PTEN, neurofibromatosis type 1 (NF1), RB1, isocitrate dehydrogenase 1 
(IDH1), and IDH2 have also been detected with varying frequencies, as have EGFR 
extracellular domain mutations, including EGFR variant III (EGFRvIII). Also, an integrated 
analysis of the wealth of genetic lesions already identified has revealed that these genomic 
lesions cluster into three core pathways: (a) receptor tyrosine 
kinase/RAS/phosphatidylinositol 3 kinase (RTK/RAS/PI3K) signaling (altered in 88% of 
GBMs); (b) p53 signaling (altered in 87% of GBMs); and (c) Rb signaling (altered in 78% 
of GBMs) [132]. 
 
PI3K /Akt/PTEN pathway 
Among the pathways altered in glioblastomas there is also the phosphatidylinositol 3-kinase 
(PI3K)/Akt (PKB)/PTEN (Phosphatase and tensin homolog) signalling. PI3K are a family of 
kinases that phosphorylate membrane lipids, in particular phosphoinositides and 
phosphatidylinositols, such as the phosphatidylinositol 4,5-bisphosphate (PtdIns (4,5) P2) 
which is converted in phosphatidylinositol 3,4,5-triphosphate (PtdIns (3,4,5) P3). 
PI3K activation can occur through G proteins coupled receptors or growth factors tyrosine-
kinases receptor. Upstream receptor tyrosine kinases (RTKs), such as EGFR, activate class 
IA PI3Ks. The binding of the p85 regulatory subunit of PI3K to phosphotyrosine residues on 
activated RTKs leads to a conformational change in p85, releasing the inhibition of the 
catalytic subunit p110 (a, b, and d isoforms) of PI3K. The PtdIns (3,4,5) P3 binds to different 
cytosolic proteins, including Akt which undergoes a conformational change that facilitates 
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its activation through phosphorylation in correspondence of the two amino acid residues 
T308 and S473 by phosphoinositide-dependent kinases (PDK) 1 and 2, respectively (Fig.1).  
 
 
 
 
Figure 1: Schematic representation of the PI3K pathway and its main components. Solid lines 
represent activation; dashed lines represent inhibition. 4EBP1, eukaryotic initiation factor 4E binding 
protein 1; ERK, extracellular signal-related kinase; IRS1, insulin receptor substrate 1; MEK, 
mitogen-activated protein/ERK kinase; mTORC1/2, mammalian target of rapamycin complex 1/2; 
PI3K, phosphatidylinositol 3-kinase; PIP2, phosphatidylinositol 4,5-bisphosphate; PIP3, 
phosphatidylinositol 3,4,5-trisphosphate; PDK1, 3-phosphoinositide dependent protein kinase-1; 
PTEN, phosphatase and tensin homolog; RAS, rat sarcoma oncogene; Rheb, rat homolog enriched in 
the brain; S6K, S6 kinase; TSC, tuberous sclerosis protein. 
Image from:  Wen et al. Neuro-Oncology, 2012  
 
PTEN is a phosphatase that negatively regulates the PI3K/Akt pathway, by converting 
PtdIns (3,4,5) P3 in PtdIns (4,5) P2, thus directly antagonizing PI3K activity. Akt is a key 
regulator of cell proliferation and survival pathways. It is a Serine/Threonine kinases able to 
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inhibit apoptosis, promote cell proliferation and regulate lipids and glucose metabolism, cell 
movements and vesicle trafficking.  
High levels of phosphorylated/activated Akt and deletions or mutations in the PTEN gene 
are the most common alterations of the PI3K/Akt signalling in glioblastomas. These changes 
are crucial in determining the GBM malignant features, such as rapid tumour growth, 
invasiveness, resistance to cytotoxic treatments and massive angiogenesis [124, 133, 134]. 
 
p53 pathway 
The p53 protein is one of the most important tumour suppressors. Its expression is up-
regulated in response to conditions of cellular stress, such as γ and UV radiation, hypoxia, 
DNA damage and inappropriate oncogene activation. p53 acts as a transcription factor 
promoting the expression of genes that block the cell cycle and genes that repair DNA. If the 
amount of damage is beyond the cell’s capacity for repair, p53 favours the expression of 
genes involved in apoptosis, promoting cell death.  
p53 inactivating mutations are frequent in secondary GBM. Alterations of regulators of p53 
levels and/or activity are common in primary GBM. For example, Mdm2 protein is a 
negative regulator of p53: Mdm2 binds to p53 promoting its ubiquitination and subsequent 
degradation via proteasome. Mdm2 is overexpressed in some GBM. Furthermore, the 
p14
ARF
 protein, which negatively regulates the Mdm2 ability to bind p53, is often deleted in 
malignant gliomas or the corresponding gene is methylated so that its expression is 
inhibited. The abnormal p53 pathway functioning leads to a greater tolerance to DNA 
damages resulting in genomic instability [135, 136]. 
 
pRb pathway 
The retinoblastoma protein (pRb) is a tumour suppressor involved in the regulation of the 
cell cycle, controlling cells transition from the G1 into the S phase. Cyclins/cyclin-
dependent kinase (Cdk) complexes and Cdk inhibitors play a fundamental role in the 
regulation of cell proliferation. In particular, the cyclin D/Cdk4 complex catalyses the pRB 
phosphorylation resulting in the release of E2F transcription factors sequestered by the pRB 
binding, which are essential for the expression of the S-phase-genes, thus inducing DNA 
synthesis. Moreover, the p16
INK4a 
protein inhibits cell cycle progression, negatively 
regulating the formation of the complex cyclin D/Cdk4. Inactivating mutations of pRB and 
p16
INK4a 
or the amplification of genes coding for Cdk4 and cyclin D are typical features of 
53 
 
glioblastomas. All of these changes cause the pRB inability to bind E2F, resulting in an 
uncontrolled cell cycle progression from G1 to S phase [135, 136]. 
 
Ceramide in Glioblastoma 
Cer is known to play an important role in the evolution of neoplastic tumours, being 
involved as a mediator in the signal transduction mechanisms that control growth arrest, 
differentiation, senescence and cell death [16]. Different studies have demonstrated that the 
generation of Cer in response to cytotoxic therapy is a key step leading to cell death. In 
gliomas, the involvement of an altered regulation of the Cer-mediated signalling pathways is 
strongly supported by the evidence for an inverse association between Cer intracellular 
levels and the progression of the tumour malignancy a lower content of Cer corresponds to a 
higher grade of malignancy. It was also demonstrated that Cer levels are directly related to 
patient survival: a low intracellular Cer content is a negative prognostic factor [137]. 
The metabolic pathways involved in the control of Cer levels in glial cells include enzymes 
of its metabolism (SMS, SPT, SMases) and its transport from the ER to the Golgi apparatus 
for the biosynthesis of complex sphingolipids.  
It has been demonstrated that, in glioma cells, the administration of Δ9-
tetrahydrocannabinol, the main active ingredient in marijuana, induces an accumulation of 
Cer in the ER through the stimulation of the "de novo" synthesis, resulting in apoptotic cell 
death [138]. Furthermore, the anti-proliferative effect of nitric oxide in glioma cells is 
associated to the inhibition of Cer vesicular transport from the ER to the Golgi apparatus 
[139]. Of interest, in glioma cells the PI3K/Akt signalling is able to regulate the sphingolipid 
metabolism promoting Cer vesicular transport, resulting in a reduction of the intracellular 
levels of this molecule and an increased synthesis of complex sphingolipids [140]. 
Moreover, Cer-mediated caspase activation has been implicated in the γ-radiation-induced 
apoptosis in U87MG glioma cells lacking functional p53 [141]. In the same cell line, TNF-α 
activates both neutral and acid SMases in a p53-mediated ROS-dependent or -independent 
pathway that results in Cer production, which, in turn, induces apoptotic cell death [142].  
Interestingly, Cer induces not only apoptosis but also caspase-independent and/or non-
apoptotic cell death in glioma cells. It has been demonstrated that administration of C2-Cer 
results in non-apoptotic cell death induction that can be inhibited by the constitutive active 
form of Akt [143]. It has been shown that C2-Cer induced cell death via autophagic 
mechanisms [144]; moreover, natural Cer has been recently implicated in cannabinoid-
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induced and in Temozolomide-induced autophagic death in U87MG and T98G glioblastoma 
cells, respectively [145].  
All this evidence suggests that the modulation of Cer intracellular levels can be crucial in 
determining the survival or death of glioma cells. Many anticancer drugs such as etoposide, 
doxorubicin, paclitaxel, cisplatin, cause an increase of the intracellular Cer levels [17]. 
Consequently, tumour cells that possess an aberrant Cer metabolism develop resistance to 
these cytotoxic treatments, thereby determining their clinical failure.  
 
Sphingosine-1-phosphate in Gliobastoma 
A growing body of evidence has implicated S1P and the genes involved in its synthesis, 
catabolism and signalling in various aspects of oncogenesis, cancer progression and drug- 
and radiation resistance [16]. S1P has emerged as an onco-promoter molecule in different 
tumours, including GBM [146-148]. Notably, it has been previously documented that S1P 
enhances proliferation [149], motility, invasiveness and malignant behavior of GBM cells 
[150]. As an indication of the importance of this molecule, different studies have reported 
that GBM cell lines and tissue specimens show an high SphK1 expression [151, 152] which 
correlates with a worst prognosis and a poor patient survival [153] and that silencing or 
pharmacological inhibition of both SphK1 and SphK2 decreases the proliferation rate in 
GBM cells, preventing their entry into the cell cycle [151, 153].  
It has been reported that glioma cells are able not only to produce S1P, but also to release it 
in the extracellular milieu [152, 154]. This evidence suggests that S1P may play an 
important role as autocrine/paracrine messenger in GBM. 
Furthermore, it has been extensively demonstrated that glioblastoma cells commonly 
express S1P receptors, S1P1, S1P2, and S1P3 and very low levels of S1P5 [149, 155, 156], all 
contributing to GBM cell growth and invasion through distinct, but overlapping 
mechanisms. For example, it has been demonstrated that, through activation of S1P1, S1P 
up-regulates the expression of urokinase plasminogen activator (uPA), a potent stimulator 
involved in cancer cells invasion, in human glioblastoma multiforme cells [157]. 
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AIM 
S1P and Cer have emerged as bioeffector molecules, involved in the control of several 
fundamental biological processes such as cell growth, differentiation and survival [16].  
Recent significant progress in understanding the role of these bioactive sphingolipids has 
identified crucial roles for these molecules in both cancer development and resistance [3, 14-
17]. Emerging evidence suggest that S1P is an onco-promoter molecule enhancing 
proliferation, motility, invasiveness, and malignant behavior in different tumors, including 
glioblastomas [146-148, 158]. Moreover, S1P signaling have been implicated in the 
development of resistance to drug induced apoptosis, and escape from cell death [14].  
On the other hand, different studies have suggested that Cer generally acts as a tumor 
suppressor lipid in many cancer types through the inhibition of cell growth or induction of 
cell death and interestingly, it has been previously demonstrated that in human gliomas Cer 
levels are inversely associated with their malignant progression and poor prognosis [137]. 
Intracellular Cer accumulation represents a common feature of the cytotoxic action of many 
chemotherapeutic drugs [16, 159, 160] and the escape from Cer-mediated apoptosis is a 
critical step in the development of drug resistance; thus raising Cer levels may help to 
overcome the chemotherapeutic treatment failure [159, 161, 162]. Several enzymes of Cer 
metabolism have been shown to be involved in regulating its levels [3, 14, 15], but recently 
the biosynthetic trafficking of Cer is emerged as an important pathway involved in the 
control of Cer metabolism.  
Several lines of evidence indicate that, different anticancer drugs, including etoposide, exert 
cytotoxic effects also promoting accumulation of Cer in the ER. Thus, the transport of Cer 
from ER to Golgi apparatus can represent a key pathway for limiting Cer accumulation in 
the ER and escape from cell death. Moreover, we recently demonstrated that vesicular-
mediated Cer transport is positively regulated by the pro-survival pathway 
phosphatidylinositol 3-phosphate kinase (PI3K)/Akt [18], a known mediator of extracellular 
S1P effects.  
Based on these premises, the aim of this study was first to investigate in T98G glioma cells 
if S1P is involved in the regulation of Cer metabolism and traffic in the ER-Golgi 
compartment and, afterward, if S1P, by this way, can affect cell toxicity arising from Cer 
accumulation in the ER. 
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MATERIALS AND METHODS 
 
Materials 
All reagents were of analytical grade. Dulbecco’s modified Eagle’s medium (DMEM), 
Thiazolyl Blue Tetrazolium Bromide (MTT), fatty acid-free bovine serum albumin (BSA), 
Myriocin (MYR), Pertussis Toxin (PTX), Brefeldin A (BFA), fumonisin b1 (Fb1) and 
Etoposide were purchased from Sigma (St. Louis, MO, USA). Fetal calf serum (FCS) was 
from Cambrex (Walkersville, MD, USA). D-erythro- Sphingosine 1-Phosphate (S1P) e 
LY294002 were purchased from Enzo Life Sciences (Farmingdale, NY, USA). D-erythro-
[3-
3
H]sphingosine (Sph) (21.2 Ci/mmol) was from PerkinElmer Life Science (Boston, MA, 
USA). High performance thin layer chromatography (HPTLC) silica gel plates were from 
Merck (Darmstadt, Germany). N-(4,4,-difluoro-5-,7-dimethyl-bora-3a,4a-diaza-s-indacene-
3-pentanoyl) sphingosine (BODIPY-C5Cer) was from Invitrogen-Molecular Probes (Italy). 
LipofectAMINE 2000
®
 and the Stealth RNAi were from Invitrogen (Carlsbad, CA, USA). 
The antibody recognizing Phospho-Akt (Ser473) was from Cell Signaling Technology, Inc. 
(Danvers, MA, USA). The antibody recognizing GAPDH was from Santa Cruz 
Biotecnology (Santa Cruz, CA, USA). The antibody recognizing Cert was from Bethyl 
Laboratories (Montgomery, TX, USA Secondary anti-rabbit Horse Radish Peroxidase 
(HRP)-conjugated antibody were from Santa Cruz Biotechnology (Santa Cruz, CA, USA). 
SuperSignal WestPico Chemioluminescent Substrate and SuperSignal WestFemto 
Maximum Sensitivity Substrate were from Thermo Scientific (Rockford, IL, USA). 
 
Cell culture 
We used the human glioma cell line T98G derived from a glioblastoma, which was 
purchased from the American Tissue Culture Collection (Rockville, MD) and cultured as 
recommended by the supplier. The cells were grown at 37°C in DMEM supplemented with 
10% FCS, 1 mM Na-pyruvate, 2 mM L-glutamine, 100 U/ml penicillin, 100 μg/ml 
streptomycin and 0.25 μg/ml amphotericin B in a fully-humidified incubator containing 5% 
CO2 and 95% air. The cells were starved of serum before the treatments, and thereafter kept 
under serum-free conditions.  
 
Immunoblotting 
In order to detect Akt phosphorylation, the cell extracts (40 μg proteins) were analysed by 
means of Western blotting. In brief, the T98G glioma cells were lysed with Akt buffer 
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(20mM Tris-HCl pH 7.4, 150 mM NaCl, 1% NP-40, 10 mM sodium fluoride, 1mM EDTA, 
10mM Na4P2O7, 1mM Na3VO4, 2 μg/ml pepstatin, 2 μg/ml leupeptin, 2 μg/ml aprotinin). 
Solubilized proteins were centrifuged at 14,000 x g at 4°C for 10 min. Supernatants were 
subjected to 10% SDS polyacrylamide gel electrophoresis and transferred to nitrocellulose 
membranes. Membranes were blocked for 1 hour at room temperature in Tris-buffered 
saline (10 mM Tris-HCl, pH 7.4, 140 mM NaCl) containing 0.1% Tween-20 (TBS-T) and 
5% skim milk, and then incubated with primary antibodies against phospho-Akt overnight at 
4°C. Membranes were washed in TBS-T, and bound antibodies visualized with horseradish 
peroxidase-coupled secondary antibodies (Immunopure) and chemiluminescent substrate. 
The relative intensities of bands were quantified by densitometry. 
CERT immunoblotting was performed using si-control and si-CERT transfected cells lysed 
with CERT buffer (10mM Tris-HCl pH 7.4, 0.25M sucrose, 0.5mM phenylmethylsulfonyl 
fluoride, 1μg/ml aprotinin, 1μg/ml leupeptin, 1μg/ml pepstatin), processed and analyzed as 
previously described [11]. 
 
[
3
H]Sphingosine  metabolism 
T98G cells plated at 1.5 x 10
4
 cell/cm
2
  were grown 24 h in DMEM plus 10% FCS, serum-
starved for 24 hours and then pulsed with 0.15 Ci/ml [C3-
3
H] Sph for 1 and then chased for 
the indicated times at 37°C  in the presence or absence of 200 nM S1P. Otherwise, T98G 
cells were serum-starved for 24 hours and then incubated in serum-free medium in the 
absence or presence of 100 ng/ml PTX for 2 h. Then, cells were pulsed with 0.15 Ci/ml 
[C3-
3
H] Sph for 30 min in the presence or absence of 1 μg/ml BFA and chased for 1 h  in 
the presence or absence of 200 nM S1P and /or 100 ng/ml PTX and /or 1 μg/ml BFA. At the 
end, cells were washed twice with PBS, harvested and submitted to lipid extraction and 
partitioning as previously described [163]. The methanolized organic phase was analyzed by 
HPTLC using chloroform/methanol/water (110/40/6 by vol) as solvent system. Digital 
autoradiography of HPTLC plates was performed with Beta-Imager 2000 (Biospace, France) 
and the radioactivity associated  with individual lipids  was measured using the software  
provided with the instrument. The 
3
H-labeled sphingolipids were recognized and identified 
as previously described [163].  
 
RNA interference 
Small interfering RNA (siRNA) duplexes for human CERT were obtained with the 
BLOCK-iT™ RNAi Designer from Invitrogen. The selected sequences were S87:  
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5’-CCUCAGUAAGUGGACAAACUACAUU-3’, S424: 
5’-GGCUACUCUGCAACAUCCACCUCUU-3’ . The siRNA control is a nontargeting 
scrambled sequences of S87 and S424 oligonucleotide (NTS87; NTS424). The lack of 
targeting for other T98G genes by the designed siRNA duplexes was then checked by 
BLAST to avoid silencing of multiple genes other than CERT. T98G glioma cells plated at 
1.5x10
4
 cell/cm
2
 were maintained 24 h in DMEM plus 10% FCS and then transfected in the 
same medium with 100nM (final concentration) of S87 + S424 mix (1:1 by mol) and the non 
targeting corresponding sequences using Lipofectamine 2000 according to the 
manufacturer’s protocol. The experiments were performed 72 hours or, when indicated, 48 
hours after transfection. Specific silencing achieved was evaluated by immunoblotting. 
 
Analysis of the intracellular distribution of fluorescent ceramides 
T98G cells plated at 1.5x10
4
 cell/cm
2
 were grown on glass coverslips and transfected as 
described in the paragraph “RNA interference”. 24 h after transfection, cells were placed in 
DMEM without FCS for 24 h. First, cells were pretreated with 200nM S1P in the presence 
or absence of 10 M LY294002 for 30min in DMEM without FCS at 37°C, then they were 
incubated with 2,5 M BODIPY-C5-Cer (as 1:1 complex with fatty acid free BSA) in 
DMEM at 4 °C for 30 min [11]. Then cells were washed with DMEM without FCS  in the 
presence of 4 mg/ml fatty acid free BSA and treated with 200nM S1P in presence or not of 
10 M LY294002 for the indicated times at 37°C. Cells were then washed (three times with 
PBS) and fixed with 0.5% glutaraldehyde solution in PBS for 10 min at 4 °C. The specimens 
were immediately observed and analyzed with a fluorescence microscope (Olympus BX-50) 
equipped with a fast high-resolution CCD camera (Colorview 12) and an image analytical 
software (Analysis from Soft Imaging System GmbH).  
 
Treatment of cultured T98G cells with etoposide and Sphingosine-1-phosphate 
Serum-starved cells were incubated in the absence or presence of S1P and/or etoposide. 
Stock solutions of S1P and etoposide were prepared in PBS with fatty acid-free BSA (4 
mg/ml) and in dimethyl sulfoxide (DMSO) respectively, then added to the medium to reach 
the final concentration. At the used concentrations, DMSO had no effect on cell growth and 
viability. 
 
MTT assays 
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Cells were plated at 18000 cellls/cm
2
 and mantained in DMEM plus 10% of FCS for 
24h.Then, cells were placed in DMEM without FCS for 24h and incubated in serum-free 
medium in the absence or presence of 400 M etoposide and/or 10 M myriocin and/or 200 
nM S1P for 24 hours at 37°C. At the end of treatments, cells were washed with PBS and 
incubated with 0.8 mg/ml of Thiazolyl Blue Tetrazolium Bromide (MTT) in DMEM  
without FCS at 37°C, 5%CO
2
. After 4h cells were lysed in 2-propanol/formic acid (95:5) 
and absorbance  was measured at 570 nm. 
 
Other methods 
Total protein amount was assayed with the Comassie Blue based Pierce reagent, using 
bovine serum albumin fraction V as standard. Radioactivity was measured by liquid 
scintillation counting.  
 
Statistical analysis 
Statistical significance of differences was determined by one-way ANOVA. 
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RESULTS 
 
Role of S1P in the regulation of the PI3K/Akt pathway  
We wanted to determine whether, in T98G glioma cell line, S1P was able to induce the 
activation of PI3K/Akt pathway. The data obtained demonstrated that in our cellular model, 
the PI3K/Akt pathway is not constitutively activated. Treatment with 200 nM S1P is able to 
stimulate the phosphorylation of Akt in a time-dependent manner in T98G cells (Fig. 3A): in 
particular, already after 15 minutes of treatment with S1P, phosphorylated Akt (p-Akt) 
levels are increased, and the maximum activation of Akt was observed 30 minutes after S1P 
administration, with an increase of approximately three times of p-Akt levels compared to 
control. At longer times of treatment a progressive reduction in the levels of p-Akt to return 
to the baseline levels after 1 hour was observed (Fig.1). 
 
 
Figure 1: Effect of S1P on Akt phosphorylation in T98G glioma cells. T98G cells were serum-
starved for 24 hours and then incubated in serum-free medium in the presence or absence of 200 nM 
S1P for 2h. At the end the cells were harvested for immunoblot analysis of  p-AKT levels. GAPDH 
was used as loading control. All values are the mean + S.D. of at least three individual experiments. 
 
It is known that the PI3K/Akt pathway can be activated by S1P through G0/i protein-coupled 
receptors [64] which are expressed in glioma cells [164]. Thus, in order to verify if the S1P-
dependent activation of PI3K/Akt pathway was promoted by S1P interaction through its G0/i 
coupled receptors, we determined by immunoblotting the level of p-Akt in T98G cells in the 
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presence of S1P and pertussis toxin (PTX). PTX catalyzes the ADP-ribosylation of α subunit 
of the heterotrimeric protein Gi and Go preventing the release of GDP from the α subunit. 
Thus, PTX blocks the interaction of G protein with its receptor and downstream signal 
transduction.  
The results obtained from the densitometric analysis of the immunoblotting (Fig. 2) show 
that in cells treated with PTX, S1P is no longer able to induce an increase in Akt 
phosphorylation. These results demonstrate that S1P acts as an extracellular mediator in the 
activation of PI3K/Akt pathway. 
 
 
Figure 2: Effect of S1P and PTX on Akt phosphorylation in T98G glioma cells. T98G cells 
were  pretreated in serum-free medium for 2 h with 100 ng/ml (100μM)  PTX. At the end the cells 
were treated with 200 nM S1P for 30 min. Cells were harvested for immunoblot analysis of  p-AKT 
levels. GAPDH was used as loading control. All values are the mean + S.D. of at least three 
individual experiments. *p<0.05 
 
Role of S1P on Cer utilization for complex sphingolipids synthesis  
In order to investigate the effect of S1P on Cer metabolic use for the synthesis of complex 
sphingolipids, we performed a pulse chase metabolic study, using tritiated Sph ([C3-
3
 H] 
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Sph) as a precursor of sphingolipids; in fact, [
3
H]Sph is efficiently internalized and rapidly 
incorporated first into Cer, and then, in SM and glycosphingolipids [102]. 
T98G cells were pulsed with [³H]Sph for a pulse time of 1 hour and during different times of 
chase (15'-30'-45'-60') cells were treated with S1P. 
 
 
Figure 3:  S1P effect on [3H]Sph metabolism in T98G glioma cells. T98G cells were serum-
starved for 24 hours and then pulsed with 0.15 Ci/ml [C3-
3
H]Sph for 1 h. Then cells were chased 
for the indicated times at 37°C  in the presence or absence of 200 nM S1P. Radioactivity associated 
with each lipid was determined. Values are expressed as nCi/mg protein. All values are the mean  
S.D. of at least three individual experiments done in triplicate. 
 
CT 
S1P 
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The results obtained (Fig.3) show that in T98G cells treated with 200 nM S1P there was an 
increase in the radioactivity associated with [
3
H]SM and [
3
H]glycosphingolipids, and a 
concomitant decrease in the radioactivity associated with [
3
H]Cer with respect to untreated 
cells. 
 
Fig.4: Effect of PTX on S1P-induced [
3
H]Sph metabolism in T98G cells. T98G cells were serum-
starved for 24 hours and then incubated in serum-free medium in the absence or presence of 100 
ng/ml PTX. After 2 hours cells were pulsed with 0.15 Ci/ml [C3-
3
H] Sph for 30 min and then 
chased for 1 h  in the presence or absence of 200 nM S1P and /or 100 ng/ml PTX. Radioactivity 
associated with each lipid was determined. Values are expressed as nCi/mg protein. All values are 
the mean  S.D. of at least three individual experiments done in triplicate.* p<0.05 
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In particular, the greatest increase in radioactivity associated with SM and 
glucosylceramide+lactosylceramide is observed after 60 minutes of chase in the presence of 
S1P. The treatment induced 18% and 19% increase respectively of [
3
H]SM and 
[
3
H]glucosylceramide+[
3
H]lactosylceramide compared to control. In parallel, at the same 
time of chase, S1P leads to 14% decrease in the levels of radioactivity associated with 
[
3
H]Cer. Treatment with 200 nM S1P does not cause significant changes in the levels of 
radioactivity associated with [
3
H]Sph (data not shown). 
Overall, the results suggest a role of S1P in the modulation of Cer metabolic use direct to the 
synthesis of complex sphingolipids. 
To verify if the effect exerted by S1P was dependent on S1P binding to its receptors, we 
evaluated the effect of S1P on Cer metabolism in the presence of the Gi/Go protein coupled 
receptor inhibitor PTX. The results obtained (Fig.4) show that in the presence of PTX, S1P 
is no longer able to change the distribution of radioactivity associated with various 
sphingolipids, because the levels of radioactivity associated with [
3
H]Cer, [
3
H]SM and to 
[
3
H]glucosylceramide+[
3
H]lactosylceramide do not show significant differences compared 
to control. 
These results indicate that the effect of S1P on the modulation of Cer metabolic use is due to 
the action of S1P as an extracellular mediator. 
 
Role of S1P on Cer transport in the ER-Golgi district 
To investigate how S1P stimulates the biosynthesis of SM and GSL, we evaluated the effect 
of S1P on Cer metabolism in T98G cells treated with Brefeldin A (BFA). 
BFA is a fungal metabolite that causes persistent inactivation of Arf GTP-ase-1, which is 
crucial in mediating the formation of an intermediary compartment ER - Golgi (ERGIC) that 
give rise to the Golgi apparatus. It then determines a collapse of the Golgi apparatus that 
fuses its membrane with that of ER. Thus, in BFA treated cells, Cer synthesize in the ER is 
directly availablefor Golgi associated SMS and GCS. 
As shown in fig.5, the results indicate that treatment with BFA, a condition in which Cer 
does not need any transport system to move from the ER to the Golgi, determines a 83% 
decrease of the radioactivity associated to [
3
H]Cer and in an increase of 35% and 95% 
respectively of the radioactivity associated with [
3
H]SM and 
[
3
H]glucosylceramide+[
3
H]lactosylceramide, compared to control. 
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In the presence of BFA, the treatment with S1P is not able to induce significant changes in 
the levels of radioactivity associated with the different tritiated sphingolipids compared to 
BFA treated cells. 
 
 
Figure 5: Effect of BFA on S1P-induced [
3
H]Sph metabolism in T98G cells. Cells were serum-
starved for 24 hours and then pulsed with 0.15 Ci/ml [C3-
3
H] Sph for 30 min at 37°C in the 
absence or presence of 1 μg/ml BFA. Then cells were chased for 1 h  in the presence or absence of 
200 nM S1P and /or 1 μg/ml BFA. Radioactivity associated with each lipid was determined. Values 
are expressed as nCi/mg protein. All values are the mean  S.D. of at least three individual 
experiments done in triplicate. *p<0.05 
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These data suggest that S1P effect on Cer metabolism is exerted through the regulation of 
Cer transport from the ER to the Golgi apparatus and does not involve a regulation of SMS 
and GCS. Moreover, we wanted to evaluate the effect of S1P specifically on Cer vesicular 
traffic. To this purpose we performed a microscopy fluorescence studies using the Cer 
analogue BODIPY-C5Cer  that mimics the behavior of natural Cer [106] , in CERT silenced 
cells. In these experiments the level of silencing of CERT in T98G cells evaluated by 
immunoblotting was ˃95% (Fig.6). In T98G silenced cells, we evaluated the kinetics of 
transport of the BODIPY-C5-Cer, that mimics the behavior of natural ceramide [106], 
between the ER and the Golgi apparatus after treatment with 200 nM S1P (Fig.7).  
 
 
Figure 6: Effect of CERT down regulation in T98G glioma cells. Cells grown in DMEM 
supplemented with 10% FCS were transfected with a mix of H87 and H424 siRNA for CERT 
(siCERT) and the corresponding non targeting NT87 and NT424 as control (siNT) as described in 
Mat. and Meth. and analyzed for CERT levels. 72 hours after transfection cells were washed twice 
with PBS and harvested. Cell lysates (20 g of protein) from two different preparations of siNT and 
siCERT transfected cells were analyzed by immunoblotting with a polyclonal anti-CERT antibody 
and polyclonal anti-GAPDH antibody. *p<0.05 
 
 
a)
100 KDa
GAPDH
rCERT
siCT siCERT
37 KDa
 
75 KDa
siCT siCERT
0
0.4
0.8
1.2
1.6
C
E
R
T
/G
A
P
D
H
 
(a
rb
it
ra
ry
 u
n
it
s
)
* 
67 
 
This fluorescent Cer is internalized at the plasma membrane and it is distributed mainly in 
the ER. From this district, using the transport systems of natural Cer, it is transported to the 
Golgi apparatus and used for the synthesis of complex sphingolipids. The images acquired at 
time 0 'shows that the fluorescence is localized at the plasma membrane (data not shown). 
Images acquired after 5 minutes of incubation at 37°C, show that in control and S1P treated 
cells, fluorescence accumulated in the perinuclear region representative of the Golgi 
apparatus (Fig.8a). When T98G cells were treated 5 minutes without or with S1P, 
fluorescence accumulated mainly at the Golgi apparatus in 70 and 90% of the cells analysed 
respectively (Fig.8b). The results indicate that S1P modulates vesicular transport of Cer by 
increasing the speed of Cer traffic from the ER to the Golgi apparatus. 
Next, we examined whether the effect of modulation of Cer vesicular transport by S1P was 
mediated by the PI3K/Akt signal transduction pathway. To this purpose we analyzed the 
distribution of BODIPY-C5-Cer in T98G cells pretreated with the PI3K/ Akt inhibitor 
LY294002, in the presence or absence of S1P. In both cases, the accumulation of 
fluorescence at the Golgi is strongly reduced at all experimental times considered compared 
to control cells and S1P treated cells (Figure 5b and 5c).  
In cells treated with LY294002 in the presence or absence of S1P fluorescence accumulated 
mainly at the Golgi apparatus respectively in 25 and 27% of the cells analysed (Fig. 5C 
upper panel). Altogether, the results obtained demonstrate that S1P, through PI3K/Akt 
activation, increases the rate of Cer vesicular transport from the ER to the Golgi apparatus 
promoting Cer removal from the ER direct to the synthesis of complex sphingolipids. 
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Figure 8: Effect of CERT down regulation on the intracellular distribution of 
BODIPY-C5Cer in T98G glioma cells. a) T98G glioma cells grown on a coverslip were 
transfected for silencing as previously described and 48 hours after transfection, cells were pretreated 
in serum-free medium for 30 min with or without 200nM S1P and/or 10M LY294002 and then, 
cells were incubated with 2.5 M BODIPY-C5Cer for 30 min at 4°C. Labeled cells were further 
incubated at 37 °C for 5’ with or without 200nM S1P in the presence or absence of 10M 
LY294002. Images are representative of at least 5 different experiments and were identically 
processed and printed. b) the percentage of cells with colocalization of BODIPY-C5Cer and the 
Golgi apparatus in the presence or absence of S1P and/or LY294002 at the indicated times was 
determined. The data are means ± the SD. * p<0.05 
a) 
b) 
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Role of Cer in the etoposide-induced toxicity in T98G cells 
Several lines of evidence indicate that also in glioma cells accumulation of Cer is functional 
to the cytotoxic effects of different anticancer treatments [16, 160, 161]. Among these drugs, 
etoposide has been reported to induce Cer accumulation in the ER due to the activation of 
Cer biosynthesis [165]. 
To study if Cer biosynthesis at the ER was implicated in the toxic effect of etoposide we 
evaluated cell viability of T98G cells after treatment with etoposide in the presence or 
absence of Cer biosynthesis inhibitors. We used two different enzyme inhibitors: myriocin 
(MYR), direct to serine palmitoyltransferase enzyme involved in de novo pathway, or 
Fumonisin b1 (Fb1), direct to Cer synthase enzyme, involved in both salvage and in de novo 
pathway. The results in fig.9 show that, 24 hours treatment with 400 µM etoposide 
determines a decrease in cell viability of 34% with respect to control cells. Treatment with 
sub-toxic dose of MYR together with 400 µM etoposide, caused a 15% decrease in cell 
survival indicating that MYR is able to significantly reduce the toxic effect of etoposide.  
 
 
Fig. 9. Effect of etoposide and myriocin on T98G cells survival T98G cells were serum-starved 
for 24 hours and then incubated for 24 hours in serum-free medium with  400 M etoposide (ETO) 
in the presence or absence of myriocin (MYR). Cell viability was evaluated by the MTT assay. The 
viability of untreated cells was regarded as 100%. Mean ± S.D. is shown. *p<0.05 
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Furthermore, cells treatment with a sub-toxic dose of Fb1 together with 400 µM etoposide 
(Fig.10) demonstrate that Fb1 is able to almost revert the toxic effect of etoposide when 
compared to cells treated with Fb1 alone which induces a cell viability reduction of 12%.  
 
 
Figure 10: Effect of etoposide and Fumonisin b1 on T98G cells survival. b) T98G cells 
were serum-starved for 24 hours and then incubated for 24 hours in serum-free medium with  
or without 400 M etoposide (ETO) in the presence or absence of 12.5µM Fumonisin b1 
(Fb1). Cell viability was evaluated by the MTT assay.The viability of untreated cells was 
regarded as 100%. Mean ± S.D. is shown. *p<0.05 
 
These results suggest that Cer accumulation in the ER is a relevant mechanisms involved in 
the toxicity of this molecule in glioma cells. 
 
Role of sphingosine-1-phosphate and  PI3K/Akt  pathway in the etoposide-induced 
toxicity  
We therefore evaluated if the activation of Cer traffic, promoted by S1P-dependent 
PI3K/Akt activation, could affect the viability of etoposide treated cells. To this purpose, 
cell survival was assessed after treatment with etoposide in the presence or absence of S1P 
and/or LY294002, a specific inhibitor of PI3K. The results show that, after 24 hours, 
treatment with LY294002 does not cause significant changes in cell survival and the 
concomitant treatment with etoposide, S1P and LY294002 almost completely abolish the 
protective effect of S1P on cell death induced by etoposide (Fig.11).  
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Figure 11: Effect of S1P and LY294002 on etoposide-induced toxicity in T98G cells.  T98G cells 
were serum-starved for 24 hours and then pretreated, in serum-free medium, for 30 min with the 
inhibitor LY294002. Then 400 M etoposide (ETO) in the presence or absence of 200 nM S1P was 
added for 24 hours. Cell survival was evaluated by the MTT assay. The viability of untreated cells 
was regarded as 100%. Mean ± S.D. is shown.*p<0.05 
 
These results demonstrate that S1P, activating the PI3K/Akt signal, promotes Cer transport 
and metabolism, protecting cells from the toxicity induced by Cer accumulation at the ER.  
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DISCUSSION 
This investigation demonstrates that, in T98G cells, extracellular S1P is able to increase 
vesicular Cer transport from the ER to the Golgi apparatus promoting Cer conversion to SM 
and GSL, by PI3K/Akt pathway activation. We then demonstrated that the S1P-mediated 
enhancement of Cer traffic is functional to the reduction of cellular toxicity induced by Cer 
accumulation in the ER. In fact, S1P significantly promotes viability of cells treated with the 
anticancer drug etoposide that stimulates Cer byosinthesis. 
The first evidence provided by this study is that exogenous S1P exerts its effect through the 
binding of its receptors expressed in the plasma membrane, which in turn activate Akt. 
These results are in agreement with the literature that demonstrate that S1P can act as a 
potent onco-promoter molecule in glioblastomas [149, 150, 166] with an autocrine/paracrine 
effect; infact, glioma cells do express S1P receptors, and S1P administration promotes their 
proliferation, migration, and invasivity [149, 166]. Moreover, it is emerged that S1P acts in 
different cell types, including glioma cells, activating PI3K/Akt pathway [167]. 
Furthermore, we have shown in previous papers [18, 101] that the PI3K/Akt pathway is 
involved in the regulation of Cer vesicular transport from the ER to the Golgi apparatus. In 
this investigation, we first demonstrated that, in T98G glioma cells, S1P is able to increase 
the rate of Cer vesicular flow activating Cer metabolism direct to the biosynthesis of 
complex sphingolipids. The metabolic data obtained administering to the T98G cells the 
radioactive precursor [
3
H]Sph indicate a role of S1P in the modulation of Cer metabolism, 
favouring Cer use direct to the synthesis of SM and glycosphingolipids.  Moreover, S1P in 
the presence of PTX, is no longer able to modify Cer utilization indicating that the effect of 
S1P on the modulation of Cer metabolic use is due to the action of S1P as an extracellular 
mediator. Additionally, results obtained with BFA demonstrate that, in T98G glioma cells, 
the target of S1P action on Cer metabolism is the step of Cer transfer from ER to the Golgi 
apparatus. In fact, when cells were treated with BFA, which causes Golgi disassembly and 
redistribution to the ER [168], the conversion of Cer to both GlcCer and SM was strongly 
increased. The direct availability of Cer for SM and GlcCer synthases determined by BFA 
makes T98G glioma cells no more sensitive to S1P-dependent speeding of Cer utilization. 
This evidence further confirms that SM- and GlcCer-synthases are not the S1P target and 
strengthens the notion that the S1P-speeding Cer utilization is mainly due to an effect on its 
translocation from ER to cis-Golgi. Moreover, in cells down-regulated for CERT, which 
represent a good model to study the vesicular transport of Cer, we obtained additional 
evidence that S1P can positively influence the intracellular vesicular traffic of Cer from ER 
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to the Golgi apparatus, in agreement with previous data obtained in other cell types [115]. 
Infact, the analysis of BODIPY-C5-Cer intracellular distribution, which mimics the 
intracellular movements of natural Cer in T98G cells  knocked down for the Cer transport 
protein CERT, shows  that the fluorescence accumulation to the Golgi apparatus induced by 
S1P is reduced when the PI3K/Akt pathway is inhibited. This observation let us to 
hypothesize that S1P can increase the rate of vesicular transport of Cer from the ER to the 
Golgi apparatus, in agreement with data demonstrating that S1P positively regulates 
vesicular-mediated protein transport [108],through the activation of PI3K/Akt. 
 Different lines of evidence indicate that both aberrant activation of the PI3K/Akt survival 
pathway [169, 170] and downregulation of the death mediator Cer [137] play a critical role 
in the aggressive behavior, apoptosis resistance, and adverse clinical outcome of 
glioblastomas.  Cer accumulation at the ER represents a mechanism through which different 
antineoplasic drugs, including etoposide, promote cell death. Cer accumulation has been 
proposed to induce ER stress in different cellular types [171, 172], and in particular, in 
human glioma cells it is demonstrate that the induction of de novo Cer synthesis by 
cannabinoid promotes ER stress leading cells to apoptosis [145]. Our research demonstrates 
that S1P protect cells from the toxic effect of etoposide that acts stimulating Cer synthesis. 
In fact, in T98G cells, inhibition of Cer synthesis from both de novo and the recycling 
pathway significantly reduced the toxic effect of etoposide; furthermore, the PI3K inhibitor 
LY294002 completely abolished the protective effect of S1P on etoposide toxicity.  These 
data demonstrate that the pro-survival action of S1P is mediated by the activation of the 
PI3K/Akt, which stimulates Cer movement from ER to the Golgi apparatus; through this 
mechanism, the toxic Cer accumulation in the ER was prevented, allowing escape from cell 
death. 
The ability of the PI3K/Akt pathway to be regulated by/to regulate sphingolipid metabolism 
may be pathologically relevant in gliomas if we consider that the more malignant 
phenotypes of these tumors are associated with the up-regulation of the PI3K/Akt pathway 
[169, 170], increased amounts of SM [173] of glucosylceramide [174], and low Cer levels 
[137]. Thus, the S1P-dependent Cer removal from the ER could participate to the molecular 
mechanisms involved in the regulation of Cer levels.  Interestingly, Spiegel and Milstien in 
their review of 2003 yet discussed for a role of S1P on Cer synthesis regulation. They, based 
on different studies, reported that the dephosphorylation of S1P is a relevant way to promote 
Cer synthesis from sphingosine in the salvage pathway. Our data demonstrate a new role of 
S1P in the regulation of Cer transport and metabolism. In agreement with Spiegel and 
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Milstien, we could speculate that the pro-survival activity of S1P controlling both Cer 
biosynthesis and traffic might be the mechanism for its ability to suppress Cer-mediated cell 
death. Furthermore, S1P, by stimulating Cer metabolism, favours the maintainance of  low 
Cer levels and promotes the biosynthesis of new membranes needed for cell proliferation 
and growth, key elements in  tumor progression. Moreover, it is also tempting to speculate 
that Cer removal from the ER, as a consequence of a S1P-hyper-activated PI3K/Akt 
pathway,could also be involved in refractoriness of glioma cells to Cer-based treatments in 
particular those treatments that, in ER, act through Cer biosynthesis stimulation [16, 175].  
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CONCLUSIONS 
There is accumulating evidence that targeting sphingolipid metabolism may be useful in 
treatment of several pathologies, including cancer and diabetes. Considerable progress over 
the last few years in understanding the role and mechanism of Cer action in  cancer and 
diabetes has been made. A growing amount of evidence indicate that Cer plays a relevant 
role in these pathologies and the control of Cer metabolism may hold promise over 
established methods to cancer and diabetes therapeutics. Over-production of Cer clearly has 
a decisive role in the induction of apoptosis, just as enhanced metabolic clearance of Cer has 
a vital role in preventing the induction of apoptosis. Thus it is important to develop 
strategies to modulate Cer metabolism and levels to prevent or induce cell death. Thus, it 
makes sense to increase Cer to trigger glioma cell death and, on the other hand,  to lower Cer 
to avoid pancreatic β-cell failure. The Cer intracellular traffic from the ER to the Golgi 
apparatus represents a highly regulated step emerging in the control of Cer metabolism and 
levels. Furthermore, CERT dependent and independent pathways of Cer transport can be 
independently regulated, although the factors involved in the modulation of Cer traffic have 
to be investigated extensively. 
Altogether, the results obtained during my Ph.D. course  identify the Cer traffic as a possible 
target for new therapies against type 2 diabetes and glioblastoma. Notwhitstanding , a better 
understanding of the role of Cer traffic in cell survival and other key cell functions will open  
new perpectives to treat diseases in which alterations of Cer metabolism are involved. 
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